



INVESTIGATING THE ROLE OF DNA 
METHYLATION IN COELIAC DISEASE 
 
NERISSA LOUISE BOWCOCK 
 
A thesis submitted in fulfilment of the requirements of the degree of  
Doctor of Philosophy 
 
School of Medicine 









First and foremost I would like to acknowledge the contributions of Professor Joanne Lind. 
Jo was a wonderful mentor who was always full of advice, inspiration and passion for 
research. Jo had a brilliant and truly generous soul. I feel honoured to have been your PhD 
student and to have learnt from the best. You will be greatly missed.  
I would like to thank my supervisor Dr Christine Chiu for being a great mentor. Thank you for 
all the time and effort you invested into my PhD including the countless drafts you have read. 
Thank you for your ongoing support and enthusiasm not only throughout my candidature, but 
since my first time working alongside you in the lab as an undergraduate student. I am 
forever grateful for your continual guidance and knowledge over the past few years.  
Thank you to Dr Vincent Ho for his support and guidance during the final stages of my PhD.  
I am grateful for the support and friendship of my fellow peers at Western Sydney University. 
I will miss the regular lunchtime gatherings discussing the ups and downs of PhD life. I 
would like to thank my dearest friends for their belief in my abilities and for their listening 
ears, despite sometimes not knowing what I was talking about.  
Last, but not least, I would like to thank my parents, grandparents and James for their 
unconditional support, encouragement and love. I’m grateful for everything you have taught 
and given me over the years.  





STATEMENT OF AUTHENTICATION 
This thesis is submitted in fulfilment of the requirements of the degree of Doctor of 
Philosophy to the School of Medicine, Western Sydney University. The work presented in 
this thesis is, to the best of my knowledge, original except as acknowledged in the text. I 
hereby declare that I have not previously submitted this material, either in whole or in part, 








TABLE OF CONTENTS 
Table of Contents ................................................................................................................... i 
List of Tables ........................................................................................................................ iv 
List of Figures ....................................................................................................................... v 
Abbreviations List .................................................................................................................. vi 
List of Publications ............................................................................................................... vii 
Abstract............................................................................................................................... viii 
Chapter 1 .............................................................................................................................. 1 
Introduction and  Literature Review ....................................................................................... 1 
1.1. Coeliac Disease .................................................................................................. 2 
1.1.1 Epidemiology ................................................................................................ 2 
1.1.2 Pathogenesis ............................................................................................... 2 
1.1.3 Clinical Presentation ..................................................................................... 3 
1.1.4 Associated diseases ..................................................................................... 5 
1.1.1 HLA genetics ................................................................................................ 6 
1.1.2 Environmental factors ................................................................................... 6 
1.1.3 Diagnosis and Treatment ............................................................................. 7 
1.2. The genetics of CD .............................................................................................. 9 
1.2.1 Epigenetics................................................................................................. 10 
1.2.2 The role of epigenetics in autoimmune disease .......................................... 11 
1.3. Saliva as a surrogate for intestinal tissue........................................................... 14 
1.4. Aims & Hypothesis ............................................................................................ 15 
Chapter 2 ............................................................................................................................ 16 
Comparing DNA Methylation Profiles in Saliva and Intestinal Mucosa ................................ 16 
2.1. Introduction ....................................................................................................... 17 
2.2. Methods ............................................................................................................ 19 
2.2.1 Participant recruitment and sample collection ............................................. 19 
2.2.2 DNA extraction ........................................................................................... 19 
ii 
 
2.2.3 Illumina Infinium Human Methylation 450K BeadChip analysis................... 19 
2.2.4 Gene Ontology ........................................................................................... 21 
2.3. Results .............................................................................................................. 22 
2.4. Discussion ......................................................................................................... 31 
2.5. Conclusion ........................................................................................................ 34 
Chapter 3 ............................................................................................................................ 35 
The Effect of a Gluten-Free Diet on the Saliva DNA Methylome and Saliva Microbiome ..... 35 
3.1. Introduction ....................................................................................................... 36 
3.1.1 Gluten-free diets and the microbiome ......................................................... 37 
3.1.2 Gluten-free diets and the methylome .......................................................... 37 
3.2. Methods ............................................................................................................ 39 
3.2.1 Participant recruitment, sample collection and DNA extraction ................... 39 
3.2.2 Human Oral Microbe Identification using Next Generation Sequencing ...... 39 
3.2.3 Statistical analysis ...................................................................................... 40 
3.2.4 Illumina Infinium Human Methylation 450K BeadChip analysis................... 41 
3.3. Results .............................................................................................................. 43 
3.4. Discussion ......................................................................................................... 48 
3.5. Conclusion ........................................................................................................ 50 
Chapter 4 ............................................................................................................................ 51 
DNA Methylation Profiles in Individuals with Coeliac Disease and Healthy Controls ........... 51 
4.1. Introduction ....................................................................................................... 52 
4.2. Methods ............................................................................................................ 54 
4.2.1 Participant recruitment and selection criteria .............................................. 54 
4.2.2 DNA extraction and HLA genotyping .......................................................... 55 
4.2.3 Illumina Infinium Human Methylation 450K BeadChip analysis................... 55 
4.2.4 Statistical Analysis ...................................................................................... 56 
4.2.5 Gene Ontology ........................................................................................... 56 
4.2.6 Bisulfite Pyrosequencing ............................................................................ 57 
4.3. Results .............................................................................................................. 57 
iii 
 
4.4. Discussion ......................................................................................................... 66 
4.5. Conclusion ........................................................................................................ 69 
Chapter 5 ............................................................................................................................ 70 
Summary and future research perspectives ........................................................................ 70 
5.1. Saliva as a DNA source for DNA methylation studies ........................................ 71 
5.2. The effect of gluten on DNA methylation and the saliva microbiome ................. 72 
5.3. DNA methylation profiles in CD ......................................................................... 73 
5.4. Study limitations ................................................................................................ 74 
5.5. Future research ................................................................................................. 77 
References ......................................................................................................................... 80 
Appendices ......................................................................................................................... 99 





LIST OF TABLES 
Table 2.1: Clinical and demographical characteristics of individuals ........................ 22 
Table 2.2: Correlation of average DNA methylation across all CpG sites between 
saliva and intestinal mucosa within an individual ..................................................... 23 
Table 2.3: Top 15 hypermethylated and hypomethylated significantly differentially 
methylated probe sites ............................................................................................. 27 
Table 2.4: Top 15 hypermethylated and hypomethylated significantly differentially 
methylated regions ................................................................................................... 28 
Table 2.5: GO terms for differentially methylated genes between intestinal mucosa 
and saliva samples ................................................................................................... 29 
Table 2.6: Pathway analysis for differentially methylated genes between intestinal 
mucosa and saliva samples ..................................................................................... 30 
Table 3.1: Demographic characteristics of participants ............................................ 43 
Table 3.2: Microbial richness and diversity across the pre- and post-GFD groups .. 44 
Table 3.3: Beta diversity measures – Comparison between pre- and post-GFD 
groups ...................................................................................................................... 44 
Table 3.4: Correlation of average DNA methylation across all CpG sites before and 
after the uptake of GFD within an individual ............................................................. 45 
Table 4.1: Demographic characteristics of initial CD and healthy control cohorts .... 58 
Table 4.2: Differentially methylation positions identified between individuals with CD 
and healthy controls ................................................................................................. 59 





LIST OF FIGURES 
Figure 1.1: Main steps in the pathogenesis of CD. ..................................................... 4 
Figure 1.2: Histological features of intestinal mucosa damage in individuals with CD.
 ................................................................................................................................... 9 
Figure 2.1: Data clustering and comparison between saliva and tissue DNA 
methylation profiles. ................................................................................................. 24 
Figure 2.2: Multi-dimensional scaling ....................................................................... 25 
Figure 2.3: Scatter plot of average DNA methylation beta values from all individuals 
for 4000 random CpG sites between intestinal and saliva samples. ........................ 26 
Figure 3.1: Data clustering and comparison between pre- and post-GFD DNA 
methylation profiles. ................................................................................................. 46 
Figure 3.2: Scatter plot of average DNA methylation beta values from all individuals 
for 4000 random CpG sites between pre- and post-GFD samples. .......................... 47 
Figure 4.1: Top ranked differentially methylated regions of interest between CD and 
controls on 450k analysis. ........................................................................................ 61 
Figure 4.2: Top significantly differentially methylated CpG sites on 450k microarray 
analysis (n = 59) between CD and controls. ............................................................. 62 
Figure 4.3: Significantly differentially methylation CpG sites validated by 







CD coeliac disease 
DMP differentially methylated probe 
DMR differentially methylated region 
DNA deoxyribonucleic acid 
FDR false discovery rate 
GF gluten-free 
GFD gluten-free diet 
GO gene ontology 
IBD inflammatory bowel disease 
IBS irritable bowel syndrome 
KEGG Kyoto Encyclopedia of Genes and Genomes 
LEfSE linear discriminant analysis effect size 
MAF minor allele frequency 
NCGS non-coeliac gluten sensitivity 
OTU operational taxonomic units 
RNA ribonucleic acid 





LIST OF PUBLICATIONS 
Hearn NL, Coleman AS, Ho V, Chiu CL, Lind, JM. (2019). Comparing DNA methylation 
profiles in saliva and intestinal mucosa. BMC Genomics, 20(1):163. 
Hearn NL, Coleman AS, Ho V, Chiu CL, Lind, JM. (2017). Comparing DNA methylation 
profiles in saliva and intestinal mucosa. Australian Society for Medical Research National 
Scientific Conference. Sydney, Australia. 
Hearn NL, van der Kooi SK, Chiu CL, Lind JM. (2017). Does a gluten-free diet affect the 
methylome? Gordon Research Conference – Epigenetics. New Hampshire, USA. 
Dhananjayan, K, Gunawardena, D, Hearn, NL, Sonntag, T, Moran, C, Gyengesi, E, 
Srikanth, V, Münch, G. (2017)  Activation of Macrophages and Microglia by Interferon-ϒ and 
Lipopolysaccharide Increases methylglyoxal Production: A New Mechanism in the 
Development of Vascular Complications and Cognitive Decline in Type 2 Diabetes Mellitus? 
J Alzheimers Dis, 59(2):467-479. 
Chiu CL, Hearn NL, Lind JM. (2016) Development of a risk score for extra-intestinal 
manifestations of coeliac disease. Medicine (Baltimore), 95(15):e3286. 
Chiu CL, Hearn NL, Paine D, Steiner N, Lind JM. (2016) Does telomere shortening precede 
the onset of hypertension in spontaneously hypertensive mice? Twin Res Hum Genet, 
19(5):422-9. 
Hearn NL, Chiu CL, Lind JM. (2016). Development of a risk score for extra-intestinal 
manifestations of disease. Australian Society for Medical Research NSW Scientific Meeting. 
Sydney, Australia. 
Hearn NL, Chiu CL, Lind JM. (2015). Self-reported indicators of coeliac disease in an 
Australian cohort. EMBL Australia PhD Symposium. Melbourne, Australia.  
Chiu, CL, Jackson, KL, Hearn, NL, Steiner, N, Head, GA, Lind, JM. (2015) Identification of 






Coeliac disease (CD) is a chronic autoimmune disease characterised by mucosal 
inflammation in the small intestine in response to dietary gluten in genetically susceptible 
individuals. Current screening and diagnostic tests for CD are suboptimal as accurate 
serology and histology requires active consumption of gluten. Additionally the gastroscopy 
procedure is invasive and carries risks associated with anaesthesia and oesophageal 
perforation. Furthermore, genetic testing for CD susceptibility is only useful for its negative 
predictive value, as up to 56% of the Australian general population carry the disease 
susceptibility alleles. Multiple environmental factors have also been associated with CD 
development, but the underlying mechanisms are unknown. 
Gene-environment interactions are mediated by epigenetic modifications of the genome, and 
changes to epigenetic profiles can occur in response to changes in the environment. DNA 
methylation is a potential mechanism to partially explain how interactions between genetic 
and environmental factors combine to trigger disease development. Altered DNA methylation 
profiles have been observed in other gastrointestinal inflammatory disorders and have 
identified new pathways integral to the disease process. Altered DNA methylation profiles 
are also potential disease biomarkers with utility in disease screening if associated with 
disease state and identified in an easily accessible tissue. In the context of CD, DNA 
methylation profiles unique to CD irrespective of whether individuals are consuming gluten 
could be a valuable screening tool, particularly if the DNA methylation markers were present 
in an easily accessible tissue such as saliva. This thesis investigated the role of DNA 
methylation in CD and the feasibility of using saliva as the tissue source for these studies. 
To achieve this, the feasibility of saliva and the oral mucosa as an alternative tissue source 
for DNA methylation studies in intestinal disorders was first examined (Chapter 2). The DNA 
methylation profiles of saliva and intestinal mucosa, obtained via upper duodenal 
endoscopy, were compared within individuals with and without a CD. We found that DNA 
methylation profiles generated from saliva were of high quality and suitable for downstream 
analysis. DNA methylation profiles were positively correlated between saliva and intestinal 
mucosal tissues within an individual (intra-individual), and the differentially methylated 
regions that were identified mapped to genes with tissue specific functions. Interestingly, 
DNA methylation profiles in saliva exhibited greater variability between individuals, 
compared with intestinal mucosal profiles. This was proposed to either be a result of 
differences in disease status, CD vs non-CD, or that the CD individuals adhered to a gluten-
free diet (GFD), while the other individuals did not.  
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To investigate the impact of diet on DNA methylation profiles, we examined the effect of a 
GFD on saliva DNA methylation profiles in healthy individuals (Chapter 3). The relationship 
between microbiome composition and health has been well established, and studies have 
shown how the microbiome can influence DNA methylation. Therefore, in addition to DNA 
methylation profiles, the oral microbiome in healthy individuals was also characterised. This 
portion of the study utilised healthy non-CD individuals in order to eliminate any effect that 
CD may have on DNA methylation and the microbiome. No variations in microbial diversity 
or alterations in microbial species composition or abundance were observed following a 6 
week GFD. Similarly, no difference in saliva DNA methylation profiles were observed, which 
was not surprising given the absence of change in saliva microbiome profiles before and 
after the uptake of a GFD. This suggests that the variability observed in saliva samples in 
Chapter 2 could be due to disease state. 
Finally, DNA methylation profiles in saliva were compared between CD and non-CD 
individuals to identify whether epigenetic mechanisms are involved in the development of CD 
(Chapter 4). DNA methylation profiles of CD individuals who had been diagnosed at least 2 
years previously; were on a GFD; and who were currently asymptomatic, were compared to 
the DNA methylation profiles in age and sex-matched non-CD healthy controls. CpG sites 
within a region near the SLC17A3 gene were identified as being differentially methylated 
between the two groups, however the results could not be validated within a larger cohort, 
with methylation differences in the opposite direction being observed.  
DNA methylation has emerged as a potential mechanism for which interactions between 
genetic and environmental factors trigger development of disease. Identification of altered 
levels of methylation associated with disease states, whether preceding or following disease, 
offers the potential for discovering new pathways integral to the disease process. This thesis 
shows that saliva is a feasible DNA source alternative for epigenetic studies in intestinal 
disorders, whilst also showing a short-term GFD does not impact DNA methylation profile or 
the oral microbiome in healthy individuals. DNA methylation profiles in saliva from 
asymptomatic GFD-treated CD individuals did not differ significantly from non-CD healthy 
controls. Further research is required to confirm the direction of the methylation differences 
identified in the SLC17A3 region. Expanding the CD cohort to include newly diagnosed CD 
individuals with active disease may also produce different DNA methylation profiles that may 
be an important step in understanding the mechanisms that lead to the development of 













1.1. Coeliac Disease 
Coeliac disease (CD) is a chronic autoimmune disease characterised by mucosal 
inflammation in the small intestine in response to dietary gluten in genetically susceptible 
individuals. It is highly prevalent, affecting approximately 1% of the population worldwide (1). 
Individuals with another autoimmune condition or a family history of CD are at an increased 
risk of developing the disease (2). It has a diverse clinical heterogeneity, ranging from 
asymptomatic to severe, with symptoms including diarrhoea, weight loss and anaemia as 
well as malabsorption syndrome (3).  
1.1.1 Epidemiology 
Large epidemiological studies, comprising of testing for CD with positive serology as well as 
reported clinical diagnosis of CD, indicate CD affects approximately 1% of the population in 
Europe (4), North America (5), South America (6), the Middle East (7) and Asia (8). It is 
highly prevalent in Australia, affecting 1 in 70 Australians, with more women (1 in 60) than 
men (1 in 80) being affected (9). Estimates suggest that 80% or more of Australians with CD 
remain undiagnosed (10). Globally, the prevalence of CD has been increasing over recent 
years. Studies from Finland have shown a two fold increase in prevalence over 20 years, 
from 1980 to 2000 (11). Similarly, research in the United States which compared sera 
samples for CD related antibodies from the 1950s and records in the 2000s found the 
frequency of CD rose almost five times, from 0.2% to 1% (12).  
1.1.2 Pathogenesis 
In healthy individuals the small intestine is tolerant to absorbed nutrients whilst providing a 
barrier and immune response when exposed to pathogens. In individuals with CD there is a 
loss of immune tolerance to gluten, which is caused by a combination of genetic and 
environmental factors (1). Individuals are not born with CD but can develop it at any age. 
Dietary gluten is the key environmental stimulus for the development of disease in 
genetically susceptible individuals (13). Gluten is enriched with glutamines and prolines and 
is incompletely digested by gastric, pancreatic and brush border peptidases, leaving large 
peptides (14). In individuals with CD, ingested gluten peptides cross the intestinal epithelium 
into the lamina propria where they undergo deamidation by tissue transglutaminases (tTG). 
Deamination of gluten yields a higher concentration of negatively charged residues, 
increasing its affinity for human leukocyte antigen (HLA) class II DQ receptors on the surface 
of antigen presenting cells (APCs) (15). Antigen presenting cells present gluten epitopes to 
CD4+ T cells leading to T cell activation and secretion of pro-inflammatory cytokines. 
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Intraepithelial lymphocytes are activated and acquire a natural-killer like phenotype (16). 
Activated T cells also stimulate B cell production of anti-tTG antibodies and other gluten 
specific antibodies, all of which leads to the destruction and atrophy of intestinal villi and a 
reduction in the absorptive capacity of the mucosa (17). The main steps in the pathogenesis 
of CD are outlined in Figure 1.1.  
1.1.3 Clinical Presentation 
CD presentation can differ between individuals, which makes it challenging for clinicians to 
recognise and diagnose (10). In addition, the average time to diagnosis can range from 
months to several years (18). The clinical presentation of CD can be divided into classical 
CD, non-classical CD, and asymptomatic CD (19). Classical CD is characterised by 
symptoms or signs associated with the gastrointestinal tract such as diarrhoea, constipation, 
nausea, vomiting, flatulence, cramping, bloating, abdominal pain and steatorrhea, weight 
loss due to malabsorption and failure to thrive (20). Non-classical CD may manifest in a wide 
range of symptoms with patients presenting with extra-intestinal manifestations that are not 
always specific to CD. These can include anaemia, osteoporosis, dermatitis herpetiformis, 
neurological problems, dental enamel hypoplasia, mouth ulcers, lactose intolerance and 
depression (21). Many CD symptoms overlap with those of irritable bowel syndrome (22) 
which can delay the diagnosis of CD if it is not the first line of investigation (23). Finally, 
some individuals with CD are asymptomatic with no overt signs or symptoms. These 
individuals may have other conditions that are associated with an increased risk of CD, such 






Figure 1.1: Main steps in the pathogenesis of CD. 1. Gluten peptides are transported 
across the intestinal epithelium. 2. They are deamidated by tTG. 3. Deamidated gluten is 
presented to T cells by antigen presenting cells containing HLA-DQ2/8 molecules. 4. 
Activated gluten-reactive T cells produce high levels of inflammatory cytokines (IFN-γ) 
leading to immune mediated destruction of intestinal villi. 5. Activated T cells also stimulate B 
cell production of anti-TTG antibodies which leads to destruction of intestinal villi.   
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1.1.4 Associated diseases  
Individuals with CD have a higher prevalence of other autoimmune disorders when 
compared to the general population (25), with recent studies reporting that approximately 
35% of patients with CD have an additional autoimmune disease (26). Dermatitis 
herpetiformis is the most prevalent with approximately 25% of CD individuals also having 
this condition (27); followed by Hashimoto’s thyroiditis (24%) (26), type 1 diabetes (3-16%) 
(28) and Addison’s disease (5-12%) (29). 
Anxiety and depression are also seen in CD (30), with 21% of adolescent psychiatric 
outpatients reporting a history of psychiatric treatment before their diagnosis of CD (31). 
Another study reported the prevalence of depression in CD patients to be similar to that in 
non-CD controls (17.2% vs 16.0%, p = 0.08), however an elevated risk of depression was 
observed in patients who had both CD and type 1 diabetes (p < 0.001) (32). Increased levels 
of anxiety in patients with CD have also been observed where 16.8% of individuals with CD 
experience anxiety symptoms compared with 5.7% of the general population (33).  
Vitamin deficiencies can occur due to malabsorption caused by intestinal damage. 
Deficiencies can include vitamin D deficiency resulting in rickets; vitamin K deficiency 
leading to clotting abnormalities; calcium deficiencies; and iron and folate deficiencies 
resulting in anaemia. A study of 54 patients found mild anaemia and iron deficiency in 30% 
of patients, which resolved following a gluten free diet (34). Deficiencies in calcium and 
vitamin D can lead to osteoporosis, a known complication of CD. Low bone mineral density 
has been observed in patients with CD. Bone resorption and formation can be measured via 
biochemical markers in the blood and urine (35). Furthermore, dental enamel hypoplasia and 
abnormalities including pitting and grooving are present in up to 20-70% of patients with CD 
(36, 37).  
Individuals with CD have been shown to have an increased risk of contracting respiratory 
tract infections (38). Patients with CD have an elevated risk of invasive pneumococcal 
infection (38), tuberculosis (39) and influenza (40). It has been suggested that vitamin D 
deficiencies may be a possible mechanism for increased risk of tuberculosis, as low serum 
levels of vitamin D have been associated with an increased risk of active tuberculosis (41). 
Vitamin D promotes the innate immune system, providing protection against pathogens (42), 
and deficiencies in vitamin D may result in an impaired innate immune response.  
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1.1.5 HLA genetics 
Genetic factors play a key role in CD as individuals with a family history of disease have an 
increased likelihood of developing disease (43). HLA class II molecules are the most 
important genetic risk factor for CD (44). The HLA association in CD was first recognised in 
the 1970s with the HLA-B8 and HLA-DR3 haplotypes being associated with disease 
development (45). Subsequent studies focusing on the HLA region identified the HLA-DQ2 
haplotype as the major risk factor predisposing individuals to CD (45, 46). The HLA-DQ 
molecule contains two subunits that form a αβ-heterodimer and are encoded by HLADQA1 
and HLADQB1 respectively, which means that an individual can carry one to four copies of a 
haplotype. The α-chains and β-chains combine to form cis-haplotype isoforms, DQ2.2 and 
DQ2.5. Individuals who are homozygous for the DQ2.5 haplotype or those who have a single 
copy of the DQ2.5 haplotype are at the highest risk of developing CD (47). Individuals with 
CD carry at least one HLA-DQ2 or HLA-DQ8 haplotype. The HLA-DQ2 haplotype is found in 
90-95% of patients with CD (15), while the HLA-DQ8 haplotype is present in approximately 
5% of patients (48).  
1.1.6 Environmental factors 
Environmental factors play a significant role in triggering CD in people who are genetically 
susceptible. Age at first exposure to gluten has been associated with risk of CD with children 
who were introduced to gluten after 6 months of age more likely to develop CD (49). Season 
of birth has also been suggested as a trigger, with children in Sweden born during summer 
months more likely to develop CD when compared to children born during winter months 
(50). Antibiotic and proton pump inhibitor use (51, 52), surgeries and trauma (53) have also 
been suggested as potential triggers however the exact mechanism of how these factors 
trigger CD is unknown. 
Prior infection by microbial pathogens, that is viruses, bacteria, fungi or parasites, have been 
suggested to trigger autoimmune disease via molecular mimicry (54, 55). This occurs when 
the host’s immune system recognises amino acid sequences of microbial antigens and self-
tissue as the same complex. The infecting agent incorporates an epitope that is structurally 
similar to a self-antigen, which confuses the immune system and results in the induction of 
an immune response. Studies in Swedish populations have observed an increased risk of 
CD in infants who had three or more infectious episodes (chicken pox, common cold, 
pneumonia, gastroenteritis, whopping-cough, scarlet fever or otitis media), prior to 6 months 
of age (56). Studies have also shown that frequent infections early in life, including rotavirus, 
the most common viral cause of severe diarrhoea among young children, predicted a higher 
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risk of CD in childhood in genetically predisposed individuals (57, 58). Another Swedish 
population study observed a positive association between respiratory syncytial virus infection 
early in life (less than 2 years of age) and later diagnosis of CD (59). 
The intestinal microbiome has a significant role in metabolic, physiological and 
immunological processes (60), and can be altered by illness, medication use, and diet (61, 
62). Studies have shown that patients with active CD or untreated CD, have altered faecal 
and duodenal microbiota profiles that are partially restored following commencement of a 
GFD. Changes in levels of Firmicutes and Proteobacteria have been detected in patients 
with active CD (63, 64), while levels of anti-inflammatory and protective bacteria such as 
Bifidobacterium are decreased (65). In healthy individuals, short-term GFD interventions can 
alter intestinal microbiome composition, with decreased populations of beneficial bacteria , 
and increased populations of potentially unhealthy bacteria occurring after following a GFD 
for four weeks (66).  
1.1.7 Diagnosis and Treatment 
Diagnosis of CD occurs via serological testing and intestinal biopsy that must be undertaken 
while the individual is actively consuming a gluten containing diet. The commencement of a 
GFD prior to testing reduces CD related antibodies and intestinal histological changes, 
leading to false negative results (67). In order to ensure an accurate diagnosis, individuals 
who have commenced a GFD are required to undergo a gluten challenge. The amount and 
duration of gluten required appears highly variable. Current research suggests 
approximately 3-6g of gluten needs to be consumed daily for a minimum of two weeks in 
order to cause intestinal changes in 50-70% of affected adults and a minimum of four weeks 
to cause positive serology in 10-55% of adults (68-70). Ideally individuals should be 
encouraged to consume at minimum 3-6g of gluten daily for six weeks. In Australia, current 
practice employs serology screening to identify those suitable for confirmatory gastroscopy 
and intestinal histology. CD positive serology includes elevated tTG-IgA and elevated 
deamidated gliadin peptide-IgG (DGP-IgG) (70). Both these tests have >85% sensitivity and 
>90% specificity (71). CD serology screening is associated with up to 15% false negatives 
(72), which is why intestinal biopsy is required to formally diagnose individuals who return 
positive serology results or, in the case of negative serology results, if the patient has 
significant symptoms and high clinical suspicion of CD (24). Macroscopic clues to diagnosis 
include loss of mucosal folds, mosaic pattern, scalloping, nodularity and fissuring (73). The 
Marsh classification system is a means of characterising the spectrum of histopathological 
changes observed in the small intestine of individuals with CD (74, 75). The major 
histopathological features supportive of CD are villous atrophy (Marsh type 3), crypt 
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hyperplasia, and increased intraepithelial lymphocytosis (74, 76)(Figure 1.2). Marsh type 3 is 
sub-divided into IIIa, IIIb, and IIIc to reflect the spectrum of villous atrophy. Marsh IIIa refers 
to partial villous atrophy, IIIb refers to subtotal villous atrophy and IIIC refers to total villous 
atrophy (75). As with serological testing, ideally the biopsy should be performed after 
individuals have been consuming gluten for at least six weeks prior to biopsy. This is to 
reduce the rate of false-negative outcomes as significant mucosal architectural changes are 
not always present in CD individuals after a two week gluten challenge (68).  This is 
extremely problematic now that 10% of Australians are adopting wheat or gluten-free diets 
(GFDs), with the majority not having a formal medical diagnosis (77). Many people who 
follow these exclusion diets are unwilling or unable to resume gluten ingestion for formal 
diagnosis due to the fear of triggering unpleasant symptoms. An alternative test that is 
available for individuals on a GFD could overcome this problem. 
Genetic testing has been shown to assist in the diagnosis of CD. The role of HLA typing lies 
in its negative predictive value, as the absence of the HLA-DQ2 or HLA-DQ8 almost always 
excludes CD with a negative predictive value of more than 99% (78, 79). This is useful for 
screening family members who may be at risk of developing CD; individuals who have 
commenced a GFD and are unwilling to undergo a gluten challenge; and in the evaluation of 
patients with inconsistent serology and histology (80).  
Once a diagnosis of CD has been confirmed, the only known effective treatment is a lifelong 
GFD (21). This requires substantial patient education and motivation. Access to a dietitian, 
and follow up medical appointments to ensure strict adherence to the diet are also essential 
(78). Improvement and resolution of symptoms typically occurs within days or weeks, and 




Figure 1.2: Histological features of intestinal mucosa damage in individuals with CD.  
A – Normal villi – mucosal lining is unaffected as shown by the finger like projections. B – 
Partial atrophy I – cells on the surface of the intestinal lining are being infiltrated by 
lymphocytes, mild atrophy observed. C – Partial atrophy II – Increased lymphocytes and 
hyperplasic crypts, marked atrophy observed. D – Partial atrophy III – severe flattening and 
shrinking of villi. E – Subtotal atrophy – severe flattening and shrinking of villi. F – Total 
atrophy of villi – completely flattened villi (Adapted from (76) ).  
 
1.2. The genetics of CD 
Individuals with CD carry either the HLA-DQ2 or HLA-DQ8 haplotype. However, these 
haplotypes are present in up to 56% of the general population making them necessary but 
not sufficient for the development of CD (9). The finding that HLA genes contribute 
approximately 35% of the heritable risk, despite the heritability of CD being estimated at 80% 
(82, 83) has led to the search for other non-HLA loci. Since the first genome wide 
association study (GWAS) in 2007 (44), over 40 non-HLA loci have been associated with the 
development of CD. The majority of these loci contain candidate genes that have immune-
related functions including cytokines, chemokines, cell adhesion molecules, and T and B cell 
activators (44, 82, 84-88). The role of non-HLA genes in CD development is poorly 
understood. To date, no single region outside the HLA loci has been identified as a potential 
cause of CD; rather it is more likely that a combination of these variants will increase an 
individual’s risk of disease, and as a result, these variants are not assessed with current 
genetic tests.  
Autoimmune disorders occur more frequently in individuals with CD than in the general 
population. The overlap between CD and other autoimmune conditions and the likelihood of 
common disease pathways between the conditions has been investigated using GWAS data 
from CD, type 1 diabetes (89), rheumatoid arthritis (86) and Crohn’s disease (90) to identify 
genetic risk variants shared between the different diseases (91). Meta-analysis between CD 
and rheumatoid arthritis identified 14 risk loci that were shared between the conditions (86, 
92, 93). Subsequent investigation of these loci in a type 1 diabetes cohort CD identified the 
TAGAP locus to be significantly associated with all three diseases (92). The TAGAP gene 
encodes a T cell activation Rho GTPase activating protein suggesting that it may have a role 
in immune regulation. Interestingly, in type 1 diabetes and rheumatoid arthritis the TAGAP 
minor allele is protective, while in CD it is associated with risk. While in Crohn’s disease, a 
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meta-analysis identified TAGAP and 4 other risk loci that were shared with CD. Crohn’s 
disease is similar to CD in that it is a chronic intestinal inflammatory disorder, however unlike 
CD, the causative antigen is unknown (90). These findings indicate that while some loci are 
shared between the different autoimmune conditions, the direction of the effect can be 
disease specific (92).  
The genetic overlap between related autoimmune diseases indicates that the mechanisms 
that are responsible for disease development in one disease may also be involved in the 
development of the other. In the case of many autoimmune conditions, genetic factors do not 
fully account for disease development (94, 95). Immunological, hormonal, and other 
environmental factors are all considered important triggers in the development of an 
autoimmune disease. However, the degree to which these non-genetic factors influence 
disease susceptibility is unknown (96).  
Twin studies have shown that CD has a strong genetic component regardless of sex or HLA 
haplotype, with concordance rates among monozygotic twins ranging from 72-75%, and 
rates among dizygotic twins ranging from 9-11% (83). The variation in the concordance rates 
between genetically identical individuals highlights the contribution of non-genetic or 
environmental factors in CD development. As mentioned previously, environmental factors 
including previous viral or bacterial infection (56) and diet have been associated with CD 
development. These factors are also known to directly or indirectly induce epigenetic 
changes (97-99). Changes to epigenetic profiles affect gene expression and cell function, 
and may provide a mechanism to explain how environmental triggers contribute to 
development of CD.  
1.2.1 Epigenetics  
Epigenetic modifications are defined as stable and heritable alterations in gene expression 
and function that do not alter the DNA sequence (100). They are a bridge between genetics 
and the environment. DNA methylation; histone modification; and microRNA are the three 
types of epigenetic modifications seen in eukaryotic cells (101). These modifications regulate 
gene transcription and have a role in growth, development, differentiation, and genomic 
stability.  
Histones are highly conserved proteins in eukaryotic nuclei and are responsible for 
packaging and ordering of DNA into specialised structural units called nucleosomes (102). 
Histone proteins play essential structural and functional roles in the transition between active 
and inactive chromatin states. Histone acetylation and deacetylation has a key role in gene 
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regulation and involves the addition or removal of a lysine residue at the N-termini of histone 
tails. Histone acetylation is mediated by histone acetyltransferases and is associated with an 
open chromatin structure and gene transcription (100, 103). Histone methylation involves 
addition of methyl groups onto lysine or arginine residues and has an important role in 
transcriptional activation and inactivation, as well as gene silencing (104). 
microRNAs (miRNAs) are endogenous small RNAs of approximately 20–24 nucleotides long 
that are transcribed from DNA but not translated into proteins (105). miRNAs have a role in 
the expression of target genes at the post-transcriptional level, where they bind to the 
3′ untranslated regions of target messenger RNAs (106). miRNAs regulate the expression of 
more than 5300 genes in the human genome (107), and are involved in cellular processes 
including cell proliferation, apoptosis, control of stem cell self-renewal, differentiation, 
metabolism, development and tumour metastasis (105, 108). 
Finally, DNA methylation involves the covalent addition of a methyl group to the 5’ carbon of 
a cytosine when followed by a guanine (CpGs) (109). DNA methyltransferases catalyse the 
addition of the methyl group using S-adenosylmethionine as the methyl donor (100). DNA 
methylation can affect the expression of genes, particularly when the CpG sites are located 
in gene promoter regions. Methylation within promoter regions is associated with gene 
silencing. 
1.2.2 The role of epigenetics in autoimmune disease 
Alterations in histones marks have been observed in systemic lupus erythematosus (110), 
Graves’ disease, (111) and type 1 diabetes (112). Global histone acetylation and histone 
H3K9 methylation levels have been shown to be decreased in CD4+ T cells of systemic 
lupus erythematosus patients when compared to controls, (110). In peripheral blood 
mononuclear cells of patients with Graves’ disease, reduced global histone H4 acetylation 
levels and increased levels of histone deacetylase proteins have also been observed (111). 
In type 1 diabetes variations in histone acetylation levels between type 1 diabetes relative to 
controls, at the upstream regions of HLA-DRB1 and HLA-DQB1, have been reported. 
Increased histone acetylation at the HLA-DRB1 and HLA-DQB1 loci correlated with 
increased gene expression in response to Interferon-γ and TNFα in monocytes (112). 
Two studies have investigated miRNA profiles in patients with CD. The first study identified 
nine miRNAs that were upregulated and 21 that were downregulated in small intestine tissue 
from children with CD relative to healthy controls (113). More recently miRNA profiling was 
carried out in an adult cohort of CD with differing clinical phenotypes (114). Seven miRNAs; 
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miR-31-5p, miR-192-3p, miR-194-5p, miR-551a, miR-551-5p, miR-638 and miR-1290, were 
found to be differentially expressed between the CD groups and controls. miR-638 
expression was increased in CD individuals compared to controls and is predicted to target 
the transglutaminase gene (TGM2), the major autoantigen in CD. miR-31-5p, miR-
192/miR194 and miR551a expression was reduced in all CD groups when compared to 
controls. These microRNAs are involved in matrix remodelling, regulation of actin 
cytoskeleton and Wnt signalling (114).  
Studies have implicated miRNAs in the pathogenesis of other inflammatory and autoimmune 
diseases. In type 1 diabetes a set of 44 miRNAs were identified that were differentially 
expressed between type 1 diabetes and controls. These miRNAs are predicted to target 47 
candidate genes for type 1 diabetes. Biological pathways that had previously been 
implicated in type 1 diabetes were enriched in this gene set, indicating possible regulation by 
these miRNA (115). Altered miRNA expression has also been reported in Crohn’s disease. 
Several of the miRNAs identified have been implicated in the regulation of genes involved in 
inflammatory pathways, and other autoimmune diseases (116). 
Circulating miRNAs have emerged as an easily accessible biomarker in autoimmune 
diseases (117). Circulating miRNAs are able to be measured in most biofluids including 
blood serum and plasma. Myasthenia gravis is a chronic autoimmune neuromuscular 
disorder with elevated levels of miR-150-5p and miR-21-5p (117). Other studies have also 
shown that expression of miRNA-155, a regulator of B- and T cells and macrophages, is 
elevated in peripheral blood mononuclear cells of patients with rheumatoid arthritis (118), 
and in synovial tissue, fluid and fibroblasts in patients with osteoarthritis (119, 120). These 
studies suggest that miRNAs may carry disease specific signatures for various autoimmune 
diseases which could be used as a potential biological diagnostic marker. 
DNA methylation has emerged as a potential mechanism for which interactions between 
genetic and environmental factors combine to trigger disease development. Identification of 
altered methylation profiles that are significantly associated with disease state, offers the 
potential for discovering new pathways integral to the disease process. The Infinium Illumina 
Human Methylation 450K BeadChip array has been used to identify differences in DNA 
methylation in autoimmune diseases. 
Methylation studies in individuals with Crohn’s disease and ulcerative colitis, both 
inflammatory bowel conditions have observed multiple significantly differentially methylated 
sites between cases and controls. Three genes, FAM217B, KIAA1614, RIBC2, were 
identified as being hypermethylated in ulcerative colitis patients and associated with 
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transcriptional repression (121) while in Crohn’s disease, nineteen differentially methylated 
regions including the HLA region have been identified (122). The regions identified in 
Crohn’s disease contained genes involved in immune response processes, inflammatory 
pathways and included regions located upstream of the MHC HLA-J loci (123). Studies that 
have compared the differentially methylated regions, and the genes that map to these 
regions, between the two diseases have observed a considerable overlap. In one study 
53.7% of the Crohn’s disease associated genes were found to overlap with genes 
associated with ulcerative colitis (124). A further study found 45% of the differentially 
methylated sites in Crohn’s disease were also indicated in ulcerative colitis cases, and 97% 
of the ulcerative colitis associated differentially methylated sites were indicated in Crohn’s 
disease patients (125). These results suggest common pathways between the two 
conditions, or that they are the result of non-specific inflammation rather than disease-
specific inflammation.  
In rheumatoid arthritis genome wide evaluations of DNA methylation profiles have identified 
1859 differentially methylated loci that mapped to key genes including CHI3L1, CASP1, 
STAT3, which were hypomethylated (126). Differentially methylated regions in CD4+ T cells 
have been identified that contain genes involved immune function and cell trafficking (127, 
128). Novel methylation signatures in T and B lymphocytes have also been identified that 
can differentiate rheumatoid arthritis patients from healthy controls, highlighting the potential 
of DNA methylation as a biomarker for disease. 
Studies in type 1 diabetes (129) using discordant monozygotic twin pairs have reported 
differences in the proportions of hypo to hypermethylated CpG sites within promoter regions. 
In affected twins 69.3% of CpGs in promoter regions were hypomethylated. While another 
study investigating CD4+ T cells and CD19+ B cells in discordant twins identified a single site 
that mapped to an intergenic region downstream of the DDIT4 gene (130). The top three 
site-specific findings (MAGI2:cg14464244, FANCC:cg13600149, and 
PCDHB16:cg25340050) identified in type 1 diabetes have also been identified in studies 




1.3. Saliva as a surrogate for intestinal tissue 
Small intestinal histology, obtained via gastroscopy/endoscopy biopsy, is the gold standard 
for a definitive diagnosis of CD. The gastroscopy process is invasive, carries a degree of 
medical risk, and requires patient sedation and time off work. These factors, in addition to 
the expenses associated with the procedure, can discourage some individuals from 
obtaining a definitive diagnosis, and they will remain undiagnosed. A tissue that is easily 
accessible and reflects the pathological changes that occur in the intestine could be utilised 
as a surrogate to intestinal mucosa. This would be an attractive alternative to gastroscopies 
and biopsies.  
Saliva is an attractive alternative compared to blood or intestinal mucosa, as individuals can 
collect their own saliva using commercially available kits which stabilise the sample at room 
temperature, enabling individuals to mail the sample back to the clinic. Furthermore, the 
convenience of this method may also increase compliance rates for follow up medical 
appointments and procedures (133). The viability of saliva as a surrogate for less accessible 
tissues; including brain (134), lung/bronchial epithelium (135), and peripheral blood 
mononuclear cells (133), for DNA methylation changes has been previously demonstrated, 
with methylation profiles correlating positively between saliva and the tissue in question. To 
date, no studies have investigated the correlation between DNA methylation profiles 




1.4. Aims & Hypothesis 
Current screening and diagnostic tests are suboptimal. Accurate serology and histology, via 
biopsy, require an individual to be actively consuming gluten, which can be problematic 
given the popularity of this diet. Furthermore, the gastroscopy procedure is invasive and 
carries risk associated with anaesthesia and oesophageal perforation. Finally, genetic 
testing for the HLADQ2 or HLADQ8 susceptibility haplotypes is only useful for its negative 
predictive value, as up to 56% of the general population in Australia carry these haplotypes, 
and the vast majority do not develop CD.  
Epigenetics, specifically DNA methylation is a potential mechanism to partially explain how 
interactions between genetic and environmental factors combine to trigger disease 
development. Identification of altered methylation profiles that are associated with disease 
state, offers the potential for discovering new pathways integral to the disease process, as 
well as providing potential biomarkers. DNA methylation biomarkers that can differentiate 
between individuals with CD and healthy controls could one day provide an alternative to an 
invasive intestinal biopsy, particularly if the biomarkers are present in an accessible tissue 
such as saliva. Furthermore, the presence of these biomarkers in individuals who are not 
actively consuming gluten (on a GFD) would be beneficial as it would remove the need for 
the gluten challenge and individuals could commence a GFD immediately.  
The overall aim of this project is to identify DNA methylation changes associated with CD. 
These methylation changes will be independent of gluten consumption and be present in 
both intestinal mucosa and saliva. The methylation changes will aim to provide a better 
understanding of how the environment impacts biological processes and contributes to CD 
development.  
Specifically, we aim to: 
1. Compare DNA methylation profiles between saliva and intestinal mucosa tissue, 
in order to determine the feasibility of saliva as an alternative.  
2. Compare DNA methylation profiles in healthy controls prior to and following a 
GFD, to identify sites that are influenced by gluten consumption. 
3. Compare DNA methylation profiles between individuals with CD and healthy 









COMPARING DNA METHYLATION 




2.1.  Introduction 
Crohn’s disease, ulcerative colitis, and coeliac disease (CD) are chronic intestinal 
inflammatory disorders characterised by varying intestinal symptoms including; severe 
diarrhoea, abdominal pain and rectal bleeding; as well as extra-intestinal complications 
including anaemia and malnutrition (136). The development of these conditions is thought to 
be a result of a genetic predisposition coupled with environmental stimuli (137). The 
involvement of both genetic and environmental factors suggests that epigenetic mechanisms 
have a role in the pathogenesis of these intestinal inflammatory diseases (138). Epigenetic 
modifications are defined as stable and heritable alterations in gene expression and function 
that do not alter the DNA sequence (100). DNA methylation is a type of epigenetic 
modification which regulates gene transcription and has roles in development, differentiation, 
and genomic stability (139). It involves the addition of a methyl group to a cytosine 
nucleotide when it is followed by a guanine, which is referred to as CpG dinucleotides. In the 
mammalian genome approximately 15% of the CpG dinucleotides are found in CpG islands, 
which are defined as stretches of DNA >200 bp, with a CG content greater than 50% and an 
observed to expected ratio of CpG greater than 60% (140, 141). CpG islands are often found 
in the promoter regions of both constitutively expressed genes and tissue specific genes 
(142). Methylation of CpG islands are generally associated with gene repression. 
Epigenetic modifications can be influenced by environmental factors including diet, illness 
and smoking (143). DNA methylation has been implicated in the pathogenesis of intestinal 
inflammatory diseases, with studies in Crohn’s disease, inflammatory bowel disease, and 
ulcerative colitis demonstrating that individuals with these conditions have altered DNA 
methylation profiles in their intestinal, colon, or rectal tissue, when compared to healthy 
controls (131, 137, 144).  
Many studies have investigated the utility of DNA methylation biomarkers for disease 
screening, diagnosis, and management (145, 146). Epigenetic studies in inflammatory 
intestinal diseases have utilised either intestinal mucosal tissue or peripheral blood 
mononuclear cells (125, 147). Collection of these samples is invasive, carries the risk of 
complications, and requires trained personnel, which for large-scale research studies can be 
problematic. Saliva is an attractive alternative for epigenetic studies as it is easy to collect 
and provides high quality methylation profiles (133). In the clinical setting, saliva is also an 
attractive alternative compared to blood or intestinal mucosa, as individuals can collect their 
own saliva using commercially available kits which stabilises the sample at room 
temperature, enabling individuals to mail the sample back to the clinic. This negates the 
need for specially trained medical personnel and reduces the risk of disease transmission 
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via needle stick injury (148). Furthermore, the convenience of this method may also increase 
compliance rates for follow up medical appointments and procedures (133). Studies 
examining the suitability of saliva as a source of DNA for epigenetic and genetic research 
have shown that saliva yields DNA of sufficient quantity and quality for downstream 
applications (149).  
DNA methylation studies comparing profiles between tissue types within individuals have 
shown that regions of tissue-specific differential methylation mainly map to CpG poor regions 
(150). The viability of saliva as an alternative for less accessible tissues; including brain 
(134), lung/bronchial epithelium (135), and peripheral blood mononuclear cells (133), for 
DNA methylation studies has been previously demonstrated, with methylation profiles 
correlating positively between saliva and the tissue in question. Saliva is composed of more 
than 99% water, and also contains white blood cells and epithelial cells, which represent the 
cell types of the oral mucosa (151). The oral cavity is connected to and represents the 
entrance to the gastrointestinal tract. For studies where environmental exposures can drive 
epigenetic change, saliva and the oral mucosa is an ideal alternative for the intestinal 
mucosa given the similarities in cellular composition and environmental exposures between 
the two tissue sites.  
To date, no studies have compared DNA methylation profiles between saliva and the 
intestinal mucosa. The aim of the current study was to determine the utility of saliva for large 
scale DNA methylation research studies in intestinal conditions by investigating tissue-




2.2.1 Participant recruitment and sample collection 
Individuals undergoing an endoscopy to investigate non-cancer related epigastric symptoms 
at Campbelltown Private Hospital, NSW, Australia were recruited into this study. This study 
was approved by the Western Sydney University Human Ethics Committee (H10513), the 
South Western Sydney Local Health District Ethics Committee (HREC/16/LPOOL/305) and 
the Macquarie University Human Ethics Committee (5201700199). Following written 
informed consent, demographic, clinical, and lifestyle information was collected via 
questionnaire (152) (Appendix A). Saliva samples were collected immediately prior to the 
patient’s endoscopy using the Oragene-DNA OG500 saliva self-collection kit (DNA Genotex, 
Canada), and stored at 4°C. Intestinal biopsy samples were collected by the 
gastroenterologist during an upper endoscopy procedure, while the participant was under 
sedation. Biopsies were excised from the duodenal region of the gastrointestinal tract and 
stored at -80°C.  
2.2.2 DNA extraction 
Genomic DNA was extracted from intestinal mucosal tissue using the Qiagen DNA Mini Kit 
Tissue Spin Column Protocol (Qiagen, Germany). Saliva was incubated at 50°C for 2 hours 
followed by incubation with proteinase K at 56°C for 10 minutes. Saliva samples were 
processed using the prepIT-L2P DNA collection kit (DNA Genotek, Canada) according to the 
manufacturer’s protocol. Saliva DNA was then purified using the Qiagen DNA mini kit spin 
column protocol (Qiagen, Germany). All extracted samples were quantified and stored 
at -20°C. 
2.2.3 Illumina Infinium Human Methylation 450K BeadChip analysis 
Genomic DNA underwent sodium bisulfite conversion and was hybridized to the Illumina 
Infinium Human Methylation 450K BeadChip (Illumina, San Diego, CA). Amplification, 
hybridization, washing, labelling and scanning of the array was performed by the Australian 
Genome Research Facility (AGRF), a fee-for-service provider. Raw IDAT files containing 
signal intensities for each probe were extracted using Illumina GenomeStudio software and 
imported into RStudio using the methylumi and minfi packages (153, 154). Data quality 
control and processing steps were conducted using the methylumi and wateRmelon 
packages in R (153, 155). Filtering by detection p-values removed both failed samples and 
probes. The pfilter function was used to discard probes with a detection p-value > 0.01 in at 
least 1% samples (n = 1011) and/or a bead count less than 3 in 5% of samples (n = 240). No 
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samples were removed. Data was normalised by adjusting for background methylated and 
unmethylated intensities with the dasen function (155). Multi-dimensional scaling (MDS) 
plots of variably methylated probes in saliva and intestinal mucosa were used to confirm that 
the predicted tissue type matched the reported tissue type for each participant pre and post 
normalisation (Figure 2.2). 
Methylation measurements of a subset of probes on the microarray can be confounded by 
underlying SNPs and cross-hybridisation to other areas of the genome. To account for this, 
probes containing a SNP with minor allele frequency (MAF) > 5% within 5 bp of the single 
base extension site were removed from all analyses based on the SNP annotation data 
provided by Illumina, the Bioconductor package minfi (154), and Chen and colleagues (156). 
Probes located on sex chromosomes (X chromosome n = 11,141 and Y chromosome n = 
416), and non-cpg probes (n = 3,073) were also removed from subsequent analysis, leaving 
456,148 probes. Hierarchical clustering was performed using average linkage and 
correlation-based distances metric for clustering. Saliva contains a mixture of different cell 
types, and cell-type proportions may differ across individuals (157). Surrogate variable 
analysis using the sva package was used to identify sources of variation, including cell type 
heterogeneity within samples and potential batch effects (158, 159). sva identified two 
surrogate variables that were then adjusted for in subsequent analysis. 
Moderated paired t-tests were used to assess the association between methylation and 
tissue type at the individual probe level using the limma package (160). Prior to analysis, 
β-values were log transformed to M-values to improve sensitivity. P-values were adjusted for 
multiple testing according to the false discovery rate (FDR) procedure of Benjamini 
Hochberg. Significantly differentially methylated probes (DMPs) were selected using an 
absolute β difference of ≥20% and an adjusted p<0.001 cut-off. While DNA methylation 
studies can report effect sizes as small as 5% (125), a more stringent definition of absolute 
beta difference of 20% was used as we would expect larger differences between tissue 
types. Furthermore, these cut-offs are in line with previous studies comparing DNA 
methylation between tissues (133, 150, 161, 162). The DMRcate package (163) was then 
used to identify differentially methylated regions (DMRs), based on consecutive CpG probes 
with a mean methylation difference above a certain threshold. The inclusion threshold was 
set to beta difference ≥20%, and at least two consecutive CpGs to minimise the probability 
of randomly obtaining consecutive CpGs whose mean effect size are above 20%. 
Correlations between methylation in saliva and intestinal mucosa were measured using the 
cor.test function, at each probe site between paired samples, using Pearson’s product 
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moment correlation coefficient. A Benjamini-Hochberg adjusted p-value <0.05 was 
considered as significant.  
2.2.4 Gene Ontology 
Functional annotation analysis and gene ontology (GO) enrichment analysis was performed 
using the missMethyl package (164). The gometh function (prior.prob = TRUE) was used to 
test gene ontology enrichment for significant CpGs. In addition, the gometh function was 
used to perform pathway enrichment analysis based on the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) classification databases to identify significant pathways. Following 
this, the topGO or topKEGG function of the limma package was used to identify the most 




Intestinal mucosa and saliva samples were obtained from 10 individuals. All individuals were 
female, Caucasian, and were not current smokers. The mean age was 51.6 ± 6.1 years old, 
and the mean BMI was 28.5 ± 1.8 kg/m2. Individuals were undergoing endoscopies for 
investigations into epigastric pain and difficulty swallowing or were having routine follow up 
endoscopies for CD. All individuals with CD were currently on a gluten-free diet (GFD) and 
did not have active disease, as determined by the gastroenterologist’s endoscopy report. 
Demographic and clinical characteristics of the participants are summarised in Table 2.1. 
Table 2.1: Clinical and demographical characteristics of individuals 






1 70 30.0 Quit Difficulty swallowing Somac, Warfarin 
2 73 33.6 Never Epigastric pain  
3 67 39.9 Never Epigastric pain Nexium 
4 47 28.4 Quit Oesophageal reflux Somac 
5 19 25.4 Never Oesophageal reflux 
Nexium, Motilium, 
Mezavart 
6 49 30.1 Never 
Routine CD  
follow up 
 
7 42 26.3 Quit 
Routine CD  
follow up 
 
8 60 24.3 Never 
Routine CD  
follow up 
 
9 66 29.0 Quit 
Routine CD  
follow up 
 
10 20 17.8 Never 




DNA methylation was measured using Illumina Infinium Methylation 450K BeadChip array 
for all 20 samples (10 saliva and 10 matched intestinal samples). Following quality control 
filtering and removal of probes on sex chromosomes and probes on non-cpg sites, 456,148 
probes were included in the analysis. Hierarchical clustering based on average linkage and 
correlation-based distances showed that the saliva and intestinal tissue samples clustered 
into two distinct groups, and within the saliva cluster, individuals with CD also appear to 
cluster together (Figure 2.1A). Multidimensional scaling (MDS) of the top 1000 most variable 
sites showed intestinal mucosal tissue clustered tightly, while saliva samples appeared were 
more variable (Figure 2.2C). Overall, global DNA methylation of saliva and intestinal mucosa 
was positively correlated within an individual (Pearson’s correlation co-efficient r 0.92 - 0.95, 
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p<0.001) (Table 2.2). For 68.9% of CpG sites positive Pearson correlations between 
methylation levels of saliva and tissue samples were observed, and of these 14.8% were 
statistically significant (Figure 2.1B). A scatter plot of average DNA methylation values from 
all individuals for 4000 random CpG sites indicates methylation is in the same direction in 
saliva versus intestinal mucosal tissue samples, r = 0.94 (Figure 2.3). The distribution of 
difference in DNA methylation (|Δβ|) between saliva and tissue samples is shown in Figure 
2.1C.  
Table 2.2: Correlation of average DNA methylation across all CpG sites between saliva 
and intestinal mucosa within an individual 
Participant r-value p-value Confidence Interval 
1 0.927 p < 0.001 0.926 – 0.927 
2 0.950 p < 0.001 0.950 – 0.951 
3 0.921 p < 0.001 0.920 – 0.921 
4 0.939 p < 0.001 0.938 – 0.939 
5 0.947 p < 0.001 0.946 – 0.947 
6 0.928 p < 0.001 0.928 – 0.929 
7 0.922 p < 0.001 0.922 – 0.923 
8 0.924 p < 0.001 0.923 – 0.924 
9 0.930 p < 0.001 0.930 – 0.930 





Figure 2.1: Data clustering and comparison between saliva and tissue DNA 
methylation profiles. A) Hierarchical clustering based on correlation distances of whole 
genome methylation profiles in 20 samples – intestinal mucosa and saliva samples from 10 
individuals; B) Pearson correlation coefficients for methylation levels of saliva vs tissue for 
each of the CpG sites (positive correlations in boxed area with statistically significant 
correlations (adjusted P < 0.05) shown in red bars); C) The distribution of cg-probes plotted 





Figure 2.2: Multi-dimensional scaling. A) All samples pre-normalisation samples classified 
by tissue type; B) All samples pre-normalisation samples classified by whether individuals 
have CD; C) All samples post-normalisation samples classified by tissue type; D) All 




Figure 2.3: Scatter plot of average DNA methylation beta values from all individuals 
for 4000 random CpG sites between intestinal and saliva samples. Line represents the 
line of best fit.  
Using the filtering criterion of adjusted p <0.001, |Δβ| ≥20%, 48,541 probes were identified 
as being differentially methylated, of which 20,152 (41.5%) were hypomethylated and 28,389 
(58.5%) hypermethylated in saliva vs intestinal mucosa. The top differentially methylation 
positions are summarised in Table 2.3. Using both an effect size and the P value cut-off 
(adjusted p <0.001, mean |Δβ| ≥20%), region analysis identified 292 tissue-specific regions 
(tDMR), 21 (7.2%) hypomethylated and 271 (92.8%) hypermethylated regions between 
saliva and intestinal mucosa, which mapped to 278 annotated genes. The top regions are 




Table 2.3: Top 15 hypermethylated and hypomethylated significantly differentially 
methylated probe sites 
 




Hypomethylated   
 
 
 cg17356733 IFNGR2 TSS1500 p < 0.001 -0.84 
 cg24597363 MAEA Body p < 0.001 -0.84 
 cg01699630 ARG1 TSS1500 p < 0.001 -0.83 
 cg02052762 ANKFY1 Body p < 0.001 -0.83 
 cg09050670 CLCN7 Body p < 0.001 -0.83 
 cg24737761   p < 0.001 -0.83 
 cg25757820   p < 0.001 -0.82 
 cg01400750 ANAPC10 Body p < 0.001 -0.82 
 cg23363263 WDFY1 Body p < 0.001 -0.82 
 cg16924010   p < 0.001 -0.82 
 cg03778909 TBCD Body p < 0.001 -0.81 
 cg17852482 TBCD Body p < 0.001 -0.81 
 cg16149628   p < 0.001 -0.81 
 cg08173915 IFNGR2 TSS1500 p < 0.001 -0.81 
 cg25941751 EPAS1 3'UTR p < 0.001 -0.81 
      
Hypermethylated     
 cg00239353 IL32 TSS1500 p < 0.001 0.78 
 cg11760500 ETS1 Body p < 0.001 0.71 
 cg27341866 C19orf35 Body p < 0.001 0.70 
 cg02524983 LPP 5'UTR p < 0.001 0.69 
 cg24441810 TMEM177 TSS1500 p < 0.001 0.68 
 cg26401541   p < 0.001 0.68 
 cg07586956   p < 0.001 0.68 
 cg03738384 COTL1 Body p < 0.001 0.68 
 cg06617636 ZFP36L1 Body p < 0.001 0.68 
 cg20780180 SNX24 Body p < 0.001 0.67 
 cg23749482   p < 0.001 0.67 
 cg10111335   p < 0.001 0.67 
 cg26562691 PRKCB Body p < 0.001 0.67 
 cg20805133 PDCD1 TSS1500 p < 0.001 0.67 













Hypomethylated     
chr17:57915665-57918682 12 MIR21 p < 0.001 -0.26 
chr13:99223336-99223562 2 STK24 p < 0.001 -0.26 
chr16:84628969-84629008 2 COTL1 p < 0.001 -0.25 
chr13:97794052-97794113 2 MBNL2 p < 0.001 -0.24 
chr14:69255808-69257601 7 ZFP36L1 p < 0.001 -0.24 
chr2:238578376-238578491 3 LRRFIP1 p < 0.001 -0.24 
chr2:20776620-20776830 2 HS1BP3 p < 0.001 -0.24 
chr10:63809073-63809170 6 ARID5B p < 0.001 -0.23 
chr17:46709858-46710001 2 MIR196A1 p < 0.001 -0.23 
chr13:41064482-41064545 2 FOXO1 p < 0.001 -0.22 
chr11:8378791-8378827 2 STK33 p < 0.001 -0.22 
chr12:25541364-25541565 2 LMNTD1 p < 0.001 -0.21 
chr19:1130866-1130965 2 SBNO2 p < 0.001 -0.21 
chr1:178310534-178310650 3 RASAL2 p < 0.001 -0.21 
chr12:14849268-14849542 3 GUCY2C p < 0.001 -0.21 
     
Hypermethylated     
chr7:150786044-150786082 3 AGAP3 p < 0.001 0.40 
chr4:1294566-1295078 5 MAEA p < 0.001 0.43 
chr6:6900945-6901065 3 RREB1 p < 0.001 0.39 
chr8:29230953-29230998 2 DUSP4 p < 0.001 0.38 
chr1:9154250-9154254 2 SLC2A5 p < 0.001 0.35 
chr10:106088702-106089203 5 ITPRIP p < 0.001 0.37 
chr17:79297435-79297618 3 TMEM105 p < 0.001 0.33 
chr7:157090031-157090146 2 UBE3C p < 0.001 0.34 
chr3:122043799-122044172 4 CSTA p < 0.001 0.38 
chr15:70767183-70767649 4 UACA p < 0.001 0.39 
chr1:200983238-200983313 2 KIF21B p < 0.001 0.34 
chr1:8271918-8272277 5 SLC45A1 p < 0.001 0.33 
chr1:233248709-233249267 3 PCNX2 p < 0.001 0.36 
chr4:38859728-38859770 2 TLR6 p < 0.001 0.40 
chr8:56851846-56852290 3 LYN p < 0.001 0.32 




Functional annotation analysis of the 278 annotated genes identified cell adhesion 
(GO:0098609, GO:0007156, GO:0098742, GO:0007155), biological adhesion (GO:0022610) 
and calcium ion binding (GO:0005509) as the top most significant terms (Table 2.5). 
Pathway analysis identified apelin signalling pathway, regulation of actin cytoskeleton, 
transcriptional mis-regulation in cancer, oxytocin signalling and metabolic pathways as being 
significantly enriched pathways in these regions (Table 2.6).  
Table 2.5: GO terms for differentially methylated genes between intestinal mucosa 
and saliva samples 
GO No. GO Term Count P value Benjamini P values 
     
GO:0007156 homophilic cell adhesion via plasma 
membrane adhesion molecules 
23/154 p < 0.001 p < 0.001 
GO:0098742 cell-cell adhesion via plasma-
membrane adhesion molecules 
24/221 p < 0.001 p < 0.001 
GO:0005509 calcium ion binding 33/684 p < 0.001 p < 0.001 
GO:0098609 cell-cell adhesion 43/1124 p < 0.001 p < 0.01 
GO:0007155 cell adhesion 53/1656 p < 0.001 p < 0.01 
GO:0022610 biological adhesion 53/1662 p < 0.001 p < 0.01 
P value based on number of differentially expressed genes 





Table 2.6: Pathway analysis for differentially methylated genes between intestinal 
mucosa and saliva samples  
 Pathway Count P value Benjamini P 
values 
     
hsa04371 Apelin signalling pathway 5/137 p < 0.001 0.01 
hsa04810 Regulation of actin cytoskeleton 6/211 p < 0.001 0.01 
hsa05202 Transcriptional misregulation in cancer 6/174 p < 0.001 0.01 
hsa01100 Metabolic pathways 11/1241 p < 0.001 0.01 
hsa04022 cGMP-PKG signalling pathway 5/162 p < 0.001 0.01 
hsa04070 Phosphatidylinositol signalling system 4/97 p < 0.001 0.01 
hsa04144 Endocytosis 6/257 p < 0.001 0.01 
hsa04666 Fc gamma R-mediated phagocytosis 4/90 p < 0.001 0.01 
hsa04621 NOD-like receptor signalling pathway 4/158 p < 0.001 0.01 
hsa04020 Calcium signalling pathway 5/180 p < 0.001 0.01 
hsa04915 Estrogen signalling pathway 4/98 p < 0.001 0.02 
hsa04724 Glutamatergic synapse 4/114 p = 0.001 0.03 
hsa04662 B cell receptor signalling pathway 3/70 p = 0.001 0.03 
hsa05132 Salmonella infection 3/85 p = 0.001 0.03 
hsa04062 Chemokine signalling pathway 4/182 p = 0.002 0.04 
hsa04921 Oxytocin signalling pathway 4/152 p = 0.002 0.04 
 
P value based on number of differentially expressed genes 





2.4.  Discussion 
The present study compared DNA methylation profiles between saliva and intestinal mucosa 
within an individual, to determine the feasibility of saliva as an alternative for intestinal 
mucosal tissue for DNA methylation research studies in intestinal conditions. We found that 
methylation profiles were highly correlated between saliva and intestinal mucosa (r 0.92 - 
0.95) within an individual. This indicates that saliva has the potential to be a viable 
alternative for intestinal tissue for future DNA methylation studies. 
Saliva is an attractive alternative for DNA methylation profiling as collection is simple, non-
invasive, and high quality methylation profiles can be generated (133, 149). For participant 
recruitment in large research studies, these factors are highly beneficial for increasing 
participation as seen in a study comparing participation between blood collection (31% 
positive) and saliva collection (72% positive) (165). This could be extended to a clinical 
setting where the potential use of saliva to help screen and monitor conditions, may improve 
compliance rates for patient follow up appointments. 
The feasibility of using oral mucosa as a potential alternative for a less accessible tissue has 
been previously investigated. Methylation profiles comparing buccal epithelial swabs and 
bronchial epithelium obtained from individuals with adenocarcinoma lung cancers who 
smoke tobacco, to assess the utility of saliva for screening and diagnosing lung cancer found 
the methylation profiles of two genes involved in early lung carcinogenesis, p16 and FHIT, 
correlated strongly between saliva and bronchial samples (135). It was suggested that since 
the entire airway from oral cavity to lungs is exposed to the carcinogens from tobacco, the 
carcinogens would be able to induce similar epigenetic alterations in the oral mucosa as well 
as in the distant lung tissue. This study was the first to suggest that an environmental agent 
could induce the same epigenetic changes in the oral mucosa as it does in a distant tissue, 
prompting the suggestion that oral mucosa could be used as a surrogate tissue in early 
screening interventions for preventing lung cancer (135). In respiratory allergy, comparisons 
between peripheral blood mononuclear cells and saliva found that 96% of CpG sites were 
comparable between peripheral blood mononuclear cells and saliva (133). Further 
comparisons between saliva and blood in a population of African Americans recruited at 
urban public hospitals found 88.6% of CpG sites were comparable. This study also found 
that DNA methylation profiles between saliva and brain tissues were more similar than 
methylation profiles between saliva and blood (134).  
The oral cavity is the entrance to the gastrointestinal tract. The gastrointestinal tract is a 
muscular tube lined by a mucous membrane with similar histological organization across its 
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segments; the oral cavity, stomach, small intestine and large intestine. Oral mucosa consists 
of two layers, the surface stratified squamous epithelium and the deeper lamina propria. 
Duodenal mucosa consists of three layers, columnar epithelium with absorptive capacity 
including villi, lamina propria and a deep submucosa lined with Brunner’s glands which 
secrete mucus and bicarbonate in order to neutralise stomach acids and is responsible for 
the enzymatic breakdown of food. Enzymes found in saliva are also essential in the 
breakdown of dietary starches and fats. The similar composition and function of mucosa 
between the oral mucosa and intestinal mucosa alongside our findings of comparable 
methylation profiles between saliva and intestinal mucosa strengthens the idea that saliva 
has the potential to be used as an alternative for more invasive tissues. 
When comparing tissue types within an individual, a proportion of CpG sites will be 
differentially methylated, due to tissue-specific functions. Studies comparing methylation 
profiles between tissue types within individuals have identified tissue-specific differentially 
methylated regions (tDMRs) using the criterion absolute methylation differences >20% and 
p-value <0.001 (133, 150, 161, 162). Methylation comparisons between 17 different human 
somatic tissues, including gastric mucosa found that 2.2% of hypermethylated and 14.9% of 
hypomethylated CpG sites were commonly seen across all 17 tissue types. Comparisons 
between a specific tissue type and all other tissue types identified 14,441 tDMRs. Functional 
analysis of the tDMR found the genes that were hypomethylated in certain tissues were 
frequently associated with tissue-specific functions, while none of the hypermethylated 
genes were found to be involved in tissue-specific functions, indicating that hypomethylation 
is associated with tissue-specific functions (161).  
In the present study, 292 tDMR were identified between intestinal mucosa and saliva which 
corresponded to 278 unique genes. Pathway analysis of these genes identified apelin 
signalling pathways as being significantly enriched. Apelin is an important gut regulatory 
peptide ligand of the APJ receptor which has a role in gastrointestinal cytoprotection by 
regulating apoptosis (166, 167). The oxytocin signalling pathway was also significantly 
enriched. Oxytocin has been suggested to contribute to the control of the gastrointestinal 
motility, as it is expressed in nerve fibres along the entire human gastrointestinal tract, (168). 
The differences in methylation profiles observed are expected when comparing between two 
different tissue types.  
Samples were collected from individuals who were undergoing investigations for upper 
gastrointestinal related issues. Comparisons of methylation profiles were made within 
individuals which likely minimised any effect of the different gastric issues on the methylation 
profiles. Many upper gastrointestinal issues, for example gastro-oesophageal reflux affect 
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both the upper gastric region and the oral cavity. Despite the main damage occurring to the 
lower oesophagus, oral manifestations of gastroesophageal reflux can include a burning 
mouth sensation, tongue sensitivity, itching/burning, tooth erosion, dentinal hypersensitivity 
and temporomandibular/myofascial pain dysfunction (169, 170). Similarly, in CD where the 
typical symptoms are observed in the abdominal region, the disease may manifest in the oral 
cavity as oral ulcerations, changes in the salivary and parotid glands, and changes in the 
tongue (171). 
The gut microbiome can affect DNA methylation profiles via the production of metabolites, 
which alters the pool of compounds used in epigenetics modifications, or through inhibiting 
enzymes involved in epigenetic pathways (172). The differences in methylation profiles 
observed may be due to differences in the microbiota of these two tissues. Further 
investigations would be needed to assess if there are differences in the microbiome profiles 
between the saliva and intestinal microbiota and if these are causing the differences 
observed in the methylation profiles.  
In addition to the clustering of saliva and intestinal tissue into two distinct groups, saliva 
samples also clustered into two distinct groups. These two clusters appear to be the 
individuals with CD and individuals being investigated for other gastrointestinal disorders. All 
individuals with CD were currently on a strict GFD. Diet has been shown to modify 
microbiota populations as well as methylation profiles (62, 97, 98). Differences in microbial 
populations due to diet, or the presence of CD, could account for the clustering observed. 
Further investigations comparing DNA methylation profiles from saliva samples between CD 
and non-CD individuals in a larger dataset would be of interest as well as comparing 
methylation profiles before and after the uptake of a GFD. Furthermore, the post 
normalisation MDS plots (Figure 2.2C) shows tight clustering of intestinal samples but 
greater variations in saliva sample. This suggests that saliva is a potentially more informative 
tissue compared to intestinal mucosa with regard to DNA methylation due to the ability to 
detect differences between disease groups.  
Half of our participants were former smokers and while smoking can have long-lasting 
effects on DNA methylation patterns, it has been shown that individuals who quit smoking 
have DNA methylation profiles similar to those of non-smokers (173). It has been suggested 
however that environmental agents can induce the same epigenetic changes in the oral 
mucosa as it does in distant tissue (135). Therefore, any methylation changes caused by 
past smoking in the oral mucosa could occur in the gut as well. Comparisons were 
conducted within an individual to account for the effects of past smoking on DNA methylation 




The results from this study provide a framework for the use of saliva in DNA methylation 
research studies in intestinal conditions. It suggests that saliva has the potential to be used 
as an alternative for intestinal mucosa which would be beneficial to epigenetic research in 
inflammatory intestinal conditions by negating the need for invasive tissue collection. Overall, 
positive correlations in global DNA methylation were observed between saliva and intestinal 
mucosa tissues. The presence of inter-individual variation in saliva, particularly the clustering 
of individuals with CD compared to non-CD individuals, is of particular interest for research 
studies that aim to identify epigenetic risk factors that are associated with disease. Further 








THE EFFECT OF A GLUTEN-FREE DIET 







For individuals with coeliac disease (CD), non-coeliac gluten sensitivity (NCGS), or wheat 
intolerances, a gluten-free diet (GFD) is a clinical necessity as ingestion of gluten can result 
in immune-mediated intestinal damage, gastrointestinal symptoms, and/or other health-
related problems (174). Individuals suffering gastrointestinal symptoms as a result of NCGS 
have been shown to improve on a GFD (175, 176). It is estimated that CD and wheat 
allergies each affect 1% of the population, while NCGS affects up to 6% of the population (9, 
174, 177). Epidemiological data from Finland reported a two fold increase in the prevalence 
of CD from 1980 to 2000 (11), this increase however, is disproportionate to the recent and 
rapid growth seen in the GFD industry (178). Despite the relatively small proportion of the 
population affected by these conditions, the GFD is one of the most commonly adopted diets 
worldwide (176). Part of its popularity is driven by social media and the wellness community 
with the belief that the elimination of dietary gluten improves physical and mental health, 
through improvement of gastrointestinal function (179); the prevention of specific health 
problems such as rheumatoid arthritis (180); augmenting weight loss (181), and by 
strengthening the immune system (182).  
In Australia it is estimated that 7.3% of the general population follow a diet that avoids wheat 
and gluten despite not having CD nor NCGS (77), which is similar to statistics that have 
been reported in other parts of the world (183-185). The CSIRO Healthy Diet Score 2016, 
reported that 8.8% of Australians were avoiding gluten for reasons such as weight 
management or lifestyle choices (186). These studies indicate that the majority of individuals 
who place themselves on GFD do so with the belief that it is a healthier option, and not for 
any medical reason (184). This is despite evidence demonstrating that the elimination of 
dietary gluten does not affect inflammatory markers or overall well-being in non-coeliac 
individuals (187). Furthermore, in people self-reporting gluten sensitivity, only 16% will have 
reproducible symptoms after a blinded gluten challenge versus a placebo (188). 
Investigations into the nutritional quality of gluten-free (GF) processed foods have also found 
no nutritional advantage for GF foods, dispelling the perception that elimination of gluten 
confers a health benefit (178). Individuals who place themselves on a GFD for non-medical 
reasons are more likely to consume foods lower in fibre and micronutrients, such as Vitamin 




3.1.1 Gluten-free diets and the microbiome 
The intestinal microbiome has a significant role in metabolic, physiological and 
immunological processes (60), and can be altered by environmental factors such as illness, 
medication use, and diet (61, 62, 190). The oral cavity is part of the gastrointestinal tract, 
and after the colon, is the second most densely colonised part of the digestive tract, 
containing over 700 different types of bacteria (191). Saliva, buccal mucosa, palatal mucosa, 
and tongue dorsum house the diverse populations of the saliva microbiome, and like the 
intestinal microbiome, differences in saliva microbiome populations have been linked to 
cardiovascular disease (192) and Crohn’s Disease (193). 
Short-term GFD interventions can alter intestinal microbiome composition, with healthy 
individuals exhibiting decreased populations of beneficial bacteria (Bifidobacterium, 
B.longum and Lactobacillus), and increased populations of potentially unhealthy bacteria 
(Enterobacteriaceae and E coli) after following a GFD for four weeks (66).  
Components of the saliva microbiota, oral mucosa, throat, and tonsils are similar, and 
comprise bacteria adherent to epithelial cells shed from these mucosal surfaces (194). They 
contain bacterial species that secrete gliadin (gluten) degrading enzymes, suggesting a role 
in gluten processing (195). Elevated levels of salivary enzymatic gluten degrading activity 
and an oral microbiome enriched with gluten degrading bacteria, have been reported in 
individuals with CD on a GFD, when compared to healthy controls (196).  
3.1.2 Gluten-free diets and the methylome 
DNA methylation is an important regulator of gene transcription and has a role in growth, 
development, differentiation and genomic stability (100). Like the microbiome, DNA 
methylation profiles can be altered by illness, exposure to chemical agents, and diet (98, 99). 
Microbiota-derived metabolites are considered a primary mechanism of regulating the host 
epigenome. Changes in the microbiome can generate different metabolites which can then 
modify DNA methylation profiles of host genes. Changes to DNA methylation in genes 
involved in inflammation and metabolism have been reported in peripheral blood cells in 
individuals who followed the Mediterranean diet (97). Similarly, methylation changes in the 
promoter regions of genes involved in metabolic pathways were seen following a short-term 
high saturated-fatty acid diet (197).  
This study aimed to investigate the effect of a short-term GFD on the saliva microbiome in 
healthy individuals using the Human Oral Microbe Identification using Next Generation 
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Sequencing (HOMINGS) technique. The effect of gluten removal on DNA methylation 
profiles from saliva was also assessed using the Illumina Infinium Human Methylation 450K 
BeadChip in these individuals. By comparing DNA methylation profiles in healthy controls 
prior to and following a GFD, methylation sites that are influenced by gluten consumption 
can be identified. Further analysis identifying DNA methylation changes associated with CD 
can exclude the sites found to be different in this study as they would be caused by gluten 





3.2.1 Participant recruitment, sample collection and DNA extraction 
Participants were researchers within the School of Medicine, Western Sydney University, 
and their families. This study was approved by the Western Sydney University Human Ethics 
Committee (H10513). Following written and informed consent, demographic, clinical, and 
lifestyle information was collected from participants via a self-reported questionnaire 
(Appendix A). Inclusion criteria were age 18 years or over. Participants were excluded if they 
self-reported presence of gastrointestinal symptoms, or conditions including CD and NCGS; 
were current smokers; had been treated with antibiotics within the past 6 months; or reported 
following an exclusion-type diet (gluten free, vegan, vegetarian, dairy free, soy free, nut-
free). Prior to initiating the GFD, all participants were educated on the types of foods that 
contained gluten, and how to interpret food labels to prevent accidental gluten consumption. 
Each participant was provided with information on GF alternatives that could be used as a 
comparable substitute to help maintain their regular eating habits and limit dietary changes 
to primarily the removal of gluten. Information regarding any significant changes to dietary 
habits, dental procedures, or illnesses that occurred throughout the study period was 
collected. 
Whole saliva was collected at recruitment while participants were on a diet containing gluten, 
and then again after participants had been on a strict GFD for a period of 6 weeks. Saliva 
(2 ml) was collected using the Oragene DNA OG500 self-collection kits, as per the 
manufacturer’s recommendations (DNA Genotek, Canada). DNA was extracted as per the 
Oragene prep-IT L2P (DNA Genotek, Canada) protocol, and column purified using the 
Qiagen DNA mini kit (Qiagen, Germany) according to the manufacturer’s spin column 
protocol, and samples were stored at -20°C until analysis. 
3.2.2 Human Oral Microbe Identification using Next Generation Sequencing 
Bacterial identification was performed using HOMINGS (HOMINGS, Forsyth Institute, 
Cambridge, MA, USA). HOMINGS is a next-generation sequencing technique that consists 
of longer DNA-reads, generated through next generation sequencing and custom-made 16S 
rRNA probes (598 species-specific probes and 94 genus-specific), enabling the 
simultaneous identification of approximately 600 oral taxa (198, 199). The HOMINGS 
laboratory procedures were performed by the Forsyth Institute, Cambridge, USA a fee for 
service provider (200). In brief, 10-50 ng of DNA was PCR amplified using primers targeting 
the V3-V4 region of the 16S rRNA gene (341F and 806R). PCR amplicons were then 
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purified using AMPure beads, and 100ng of each library was pooled, gel purified and 
quantified. Finally, 12pM of the library mixture was spiked with 20% Phix, and was 
sequenced on the Illumina MiSeq (Illumina, San Diego, USA). The sequenced 16S rRNA 
reads were blasted against ProbeSeq for HOMINGS, a species-specific 16S rRNA-based 
oligonucleotide customized BLAST program developed at the Forsyth Institute, Cambridge, 
USA.  
3.2.3 Statistical analysis 
Raw sequences were generated by paired-end sequencing. Primary processing of 
sequencing reads was performed within Quantitative Insights into Microbial Ecology (QIIME, 
version 1.9.1) (201). Forward and reverse sequences were merged and sequences were de-
multiplexed using the default QIIME settings with the additional parameters: 
join_paired_ends.py - minimum base pair overlap j=70 and maximal percent different p=25; 
split_libraries.py – Phred quality score q=25. Following quality filtering, reads were clustered 
into operational taxonomic units (OTUs) through the closed reference clustering pipeline 
(pick_closed_reference_otus.py). Sequence reads were clustered against a 16S rRNA 
reference sequence, the HOMD database (202), using uclust OTU picking. Identity 
thresholds were set at 97% sequence similarity for species level assignment. Sequences 
with the same labels were clustered into one OTU and reads that failed to align with the 
reference sequence collection were excluded from downstream analysis. ChimeraSlayer 
(203) was used to identify chimeras in the OTUs and these were filtered out from the OTU 
table. An OTU table representing sample by observation matrices were constructed and 
OTUs that were represented by less than 5 reads or in less than 2 samples were filtered out 
(filter_otus_from_otu_table.py – minimum count n=5; minimum samples s=2). The remaining 
OTUs were aligned against the HOMD (version 14.51) database and used to construct a 
phylogenic tree. 
For alpha diversity analysis, samples were rarefied multiple times with a minimum sequence 
read depth of 10, maximum sequence read depth of 38987, a step size of 3905 reads per 
sample, and sequence sampling that was repeated 10 times. Species richness indices 
(observed OTUS, chao1 index) and diversity indices (Shannon, Simpson and fisher alpha 
index) were calculated between pre- and post-GFD groups. Beta diversity analysis was 
performed where the weighted and unweighted UniFrac distances were calculated using the 
OTUs identified above using samples ratified to 38987 reads per sample.  
Comparisons of alpha diversity pre- and post-GFD were performed with 
compare_alpha_diversity.py using a non-parametric two sample t-test (Monte Carlo 
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permutations). Comparisons of beta diversity were performed with compare_categories.py 
using the db-RDA and ANOSIM methods. For between group comparisons at the species 
level, the LEfSe method (204) was used, with the following parameters α <0.05 for the 
Kruskal-Wallis test and an LDA score of 2.0. This method performs a linear discrimination 
analysis coupled with effect size measurements to identify species that are associated with 
the pre- or post-GFD groups.  
3.2.4 Illumina Infinium Human Methylation 450K BeadChip analysis 
Bisulfite converted genomic DNA was hybridized to the Illumina Infinium Human Methylation 
450K BeadChip (450K array) (Illumina, San Diego, CA), which provides genome wide 
coverage containing greater than 450,000 methylation sites per sample. Amplification, 
hybridisation, washing, labelling and scanning of the 450K array was performed by the 
Australian Genome Research Facility (AGRF), a fee-for-service provider. Raw IDAT files 
containing signal intensities for each probe were extracted using Illumina GenomeStudio 
software and imported into RStudio using the methylumi and minfi packages. 
Multi-dimensional scaling plots of variably methylated probes on the sex chromosomes were 
used to confirm that the predicted sex matches the reported sex for each participant. Data 
quality control and processing steps were conducted using the methylumi and wateRmelon 
packages (155). The pfilter function was used to discard samples with a detection p-value 
> 0.01 in at least 1% samples and/or a bead count less than 3 in 5% of samples. Data was 
normalised using the dasen function (155). Probes containing a SNP with minor allele 
frequency >5% within 5 bp of the single base extension site were removed from all analyses 
based on the SNP annotation data provided by Illumina, the Bioconductor package minfi 
(154), and Chen and colleagues (156). Probes located on sex chromosomes and probes 
targeting non-CpG sites were also removed from all subsequent analysis. 
Saliva contains mixtures of different cell types, and cell-type proportions may differ across 
individuals. Surrogate variable analysis using the sva package was used to account for cell 
type heterogeneity within samples and potential batch effects (159, 205). sva identified two 
surrogate variables that were then adjusted for in subsequent analysis. 
Correlations between pre-GFD and post-GFD were measured using the cor.test function, at 
each probe site between paired samples, using Pearson’s product moment correlation 
coefficient. A Benjamini-Hochberg adjusted p-value <0.05 was considered as significant. 
Analyses were performed to test differences in DNA methylation between pre- and post-GFD 
status at the individual probe level in paired samples collected from the same individual 
before and after a GFD. Moderated paired t-tests were used to assess the association 
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between methylation and pre-post GFD status at the individual probe level using the limma 
package (160). Prior to analysis, β-values were log transformed to M-values to improve 
sensitivity. P-values were adjusted for multiple testing according to the false discovery rate 
(FDR) procedure of Benjamini Hochberg. Significantly differentially methylated probes 
(DMPs) were selected using a cut-off of a β difference of ≥5% and an adjusted p<0.05. The 
DMRcate package (163) was then used to identify significantly DMRs (adjusted p<0.05, 
minimum cpg sites = 2, mean |Δβ| ≥5%) between pre-GFD and post-GFD samples, as 





Participants were aged between 21 and 50 years (mean age 35.1 ± 3.8 years) and reported 
following a predominantly balanced Western diet. The mean BMI was 29.6 ± 4.0 kg/m2 for 
males and 19.9 ± 0.6 kg/m2 for females (Table 3.1). All participants were non-smokers, were 
not currently taking any medications, had not taken antibiotics within the past 12 months and 
did not report significant changes to diet, BMI, illness, or dental procedures throughout the 
duration of the study. 
Table 3.1: Demographic characteristics of participants 
Participant Age Ethnicity Sex BMI 
One 21 Caucasian Female 21.1 
Two 33 Asian Female 19.0 
Three 36 Caucasian Female 19.6 
Four 34 Caucasian Male 25.5 
Five 37 Caucasian Male 25.7 
Six 50 Caucasian Male 37.5 
 
HOMINGS, 16S rRNA sequencing and analysis, was performed on bacterial DNA collected 
from saliva in 6 individuals pre- and post- GFD. Following quality control, the average 
number of sequence reads per sample was 59,287, with a median sequence length of 424 
base pairs. OTUs clustering to the Human Oral Microbiome Database (HOMD) (207) 
identified 335 different taxonomic units. Within individuals, alpha diversity metrics and 
diversity estimates did not show any significant differences between pre- and post-GFD 
(Table 3.2). Similarly, no difference in overall microbial diversity (beta diversity 
measurements) and/or composition between pre- and post-GFD within individuals was seen 
(Table 3.3). The microbial composition between pre- and post-GFD samples at the species 
level was also compared using the linear discriminant analysis effect size (LEfSe) method, 





Table 3.2: Microbial richness and diversity across the pre- and post-GFD groups 




t statistic p value 
Richness 
estimates 
     
 Number of OTUs 215.7 ± 29.9 218.2 ± 15.8 -0.17 0.90 
 chao1 Index 247.6 ± 28.1 247.3 ± 19.0 -0.05 0.98 
Diversity 
estimates 
     
 Simpson Index 0.93 ± 0.01 0.93 ± 0.01 -0.46 0.64 
 Shannon Index 4.8 ± 0.2 4.9 ± 0.3 -0.48 0.61 
 Fisher alpha Index 30.2 ± 4.8 30.5 ± 2.6 -0.15 0.87 
 PD whole tree 9.8 ± 1.0 10.0 ± 0.9 -0.45 0.64 
 
Table 3.3: Beta diversity measures – Comparison between pre- and post-GFD groups 
  
test statistic p value 
Unweighted UniFrac    
 ADOSIM R statistic  -0.16 0.97 
 db-RDA F statistic 0.29 0.97 
Weighted UniFrac    
 ADOSIM R statistic  -0.08 0.67 




DNA methylation profiles derived from human genomic DNA isolated from saliva was 
generated for all 12 samples. DNA methylation pre- and post-GFD within an individual was 
highly correlated (r 0.993 - 0.996, p<0.001) (Table 3.4). Hierarchical clustering demonstrated 
clear intra-individual clustering with pre- and post-GFD samples clustered together for all 
individuals (Figure 3.1A). Post-normalisation multidimensional scaling (MDS) of the top 1000 
most variable sites showed clear intra-individual clustering with pre- and post-GFD samples 
from each individual clustering tightly together (Figure 3.1B). In Figure 3.1C the distribution 
of difference in DNA methylation (Δβ) between pre- and post-GFD samples is illustrated. 
Over 98% of the CpG probe sites had a non-significant |Δβ| difference less than 5% between 
pre- and post-GFD samples. A scatter plot of average DNA methylation values from all 
individuals for 4000 random CpG sites shows the beta values between pre- and post-GFD 
samples are comparable (Figure 3.2). The correlation coefficient (r = 0.9987) indicates that 
methylation levels were in the same direction in pre-GFD versus post-GFD samples for most 
sites. Furthermore, no single CpG site was observed to be significantly differentially 
methylated between pre- and post-GFD groups. Similarly, region analysis did not identify 
any regions with methylation differences in the same direction across consecutive CpG 
probes prior to and following uptake of a GFD.  
Table 3.4: Correlation of average DNA methylation across all CpG sites before and 
after the uptake of GFD within an individual 
Participant r-value p-value Confidence Interval 
One 0.994 p < 0.001 0.994 - 0.994 
Two 0.994 p < 0.001 0.994 - 0.994 
Three 0.994 p < 0.001 0.994 - 0.994 
Four 0.993 p < 0.001 0.993 - 0.993 
Five 0.995 p < 0.001 0.995 - 0.995 




Figure 3.1: Data clustering and comparison between pre- and post-GFD DNA methylation profiles. A) Hierarchical clustering based on 
correlation distances of DNA methylation profiles in 12 samples (A= pre-GFD, B= post-GFD from 6 individuals). B) Multi-dimensional scaling of 
the top 1000 most variable cg probes (A= pre-GFD and B= post-GFD). C) The distribution of cg-probes plotted against the difference in 





Figure 3.2: Scatter plot of average DNA methylation beta values from all individuals 
for 4000 random CpG sites between pre- and post-GFD samples. Line represents the 





The number of individuals adopting a GFD or avoiding gluten containing foods for 
non-medical reasons has increased in recent years partially due to the belief that it is a 
healthier choice (182). Many of these perceptions seem to be driven, in part, by wellness 
experts who negatively attribute gluten as the cause of health complaints and recommend 
the removal of gluten or whole food groups from the diet, despite little scientific evidence. 
This study investigated the effects of a short-term GFD on the saliva microbiome, and 
human DNA methylation profiles sourced from saliva in healthy individuals. We showed that 
short term removal of gluten did not alter saliva microbiome composition, nor did it change 
DNA methylation profiles in these individuals.  
The effect of short-term gluten removal on the gut microbiome in healthy individuals has 
previously been investigated (66, 176). Faecal samples from healthy individuals identified 
alterations in the abundance of eight bacterial species, including reduced levels of 
Veillonellacease and Ruminococcus bromii, following a GFD. Increased levels of 
Veillonellacease have been reported in Inflammatory Bowel Disease and Irritable Bowel 
Syndrome, and is thought to have a pro-inflammatory effect (208, 209). If removal of dietary 
gluten restores Veillonellacease levels, and reduces inflammation, it could explain why 
GFDs are beneficial for individuals with IBD or IBS. Ruminococcus bromii is involved in the 
degradation of cellulose and starch in the gastrointestinal tract, and produces hydrogen gas 
in the process (210). A reduction in the levels of Ruminococcus bromii and a resultant 
decrease in production of hydrogen gas may explain the beneficial effect of a GFD in 
patients with IBS.  
In the context of a healthy individual, reduced Veillonellacease levels do not alter levels of 
inflammatory biomarkers (176). Furthermore, following a 4 week GFD reduced levels of 
beneficial species including Bifidobacteirum and Lactobacillus, and increased levels of 
unhealthy species including Escherichia coli and Enterobacteriaceae in healthy individuals 
(66). That study suggested that a GFD altered the balance of the microbiome by allowing the 
overgrowth of opportunistic pathogens and caused suppression of immune regulatory 
mechanisms (66). The use of different technologies, 16S sequencing (176) versus 
fluorescent in situ hybridisation and quantitative PCR (66), to quantify the microbiome may 
account for the difference in results.  
The current study utilised HOMINGS, a 16S sequencing technique to profile the saliva 
microbiome. No variation in microbial diversity was observed following a GFD, which is 
consistent with the Bonder study, which used a shorter 4 week GFD period (176). 
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Furthermore, no alterations in microbial species composition or abundance were observed 
either. The location of microbiome sampling, oral cavity in this study versus the colon in the 
Bonder study may account for this. The oral cavity is a part of the gastrointestinal tract and 
has the highest microbial diversity, after the colon (196). Saliva contains a wide variety of 
species, some of which are present in, and others that differ distinctly, from the colon (211). 
Phyla including Firmicutes, Bacteroidetes and Actinobacteria are present in both regions, 
while Proteobacteria and Fusobacteria are found in the oral cavity (212). The oral cavity 
contains microbial species with gluten degrading activity and a role in degrading gluten 
peptides (eg. Aspergillus niger, Sphinogomonas capsulate, Rothia mucilaginosa and Rothia 
aeria) (195, 196, 213).  
Diet is known to influence epigenetic changes associated with disease (214). The gut 
microbiome can induce DNA methylation via the production of metabolites, which alters the 
pool of compounds used in epigenetic modifications, or by inhibiting enzymes involved in 
epigenetic pathways (172). Gut microbiome-derived metabolites interact with the mammalian 
epigenome by synthesising histone deacetylates and through the absorption and secretion 
of minerals that participate in epigenetic processes (215). For DNA methylation, nutritional 
metabolites of gut microbiota including methionine, folate, choline, betaine and vitamins B2, 
B6 and B12, have been suggested to influence DNA methylation patterns (215).  
No studies have investigated the effect of a GFD on DNA methylation saliva profiles in 
healthy individuals. Adherence to a Mediterranean diet over a 5 year period produced 
increases in DNA methylation in inflammation associated genes (COL18SA, LEPR, 
PLAGL1) (97). Alterations in microbiome profiles, in particular levels of Prevotella and some 
fibre-degrading Firmicutes, have also been detected in individuals following a Mediterranean 
diet (216).These microbiome and DNA methylation changes may help to explain the reduced 
mortality risk and lower incidence of cardiovascular disease that have been linked with 
adherence to the Mediterranean diet (217). 
A short-term diet study of seven weeks showed that high saturated fatty acids induced 
methylation changes in adipose tissues in genes associated with obesity and adipose tissue 
function (197). Similarly, in mice fed a high fat diet there was a reduction in promoter DNA 
methylation in the melanocortin 4 receptor (Mc4r) gene, which is important in body weight 
regulation (218). These studies demonstrate that short and long-term diet interventions can 
alter DNA methylation which may be driven through alterations in microbiome profiles.  
The current study was conducted in a small number of individuals which increases the 
likelihood of small but significant alterations in microbial diversity or DNA methylation profiles 
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being missed (Type II error). Increasing the sample size may have resulted in different 
findings, however previous studies investigating the effect of a short-term GFD on the 
microbiome utilised similar sample sizes (n=21 or n=10), and successfully demonstrated 
differences in gut microbiome composition (66, 176). Recruiting individuals to maintain a 
strict GFD was difficult and the cost of methylation analysis was prohibitive. 
GFDs are required for individuals who have CD or NCGS and are also beneficial for 
individuals who suffer from irritable bowel disease, Crohn’s and dermatitis herpetiformis 
through the improvement of gastrointestinal symptoms (219). For healthy individuals, a short 
term GFD does not appear to impact their saliva microbiome nor DNA methylation profiles. A 
GFD may however increase an individual’s risk of nutritional deficiencies (vitamin B and 
selenium) due to insufficient inclusion of suitable alternatives in the diet (220).  
3.5. Conclusion 
This study investigated the impact of a short-term GFD on the saliva microbiome and saliva 
DNA methylation in healthy individuals. No change in microbial composition or DNA 
methylation profiles were identified following uptake of a GFD. This suggests that in healthy 
individuals a GFD does not appear to impact an individuals’ health regarding their saliva 
microbiome or saliva DNA methylation profile. Further investigations utilising a larger sample 








DNA METHYLATION PROFILES IN 
INDIVIDUALS WITH COELIAC DISEASE 





Coeliac disease (CD) is a chronic autoimmune disease characterised by mucosal 
inflammation in the small intestine in response to dietary gluten in genetically susceptible 
individuals. It is highly prevalent, affecting approximately 1% of the population worldwide (1). 
CD presentation can differ between individuals, which makes it challenging for clinicians to 
recognise and diagnose (10), and the average time to diagnosis can range from months to 
several years (18).  
Genetic factors play a key role in CD as individuals with a family history of disease have an 
increased likelihood of also developing disease (43). Individuals with CD carry either the 
HLA-DQ2 or HLA-DQ8 haplotype. The HLA-DQ2 haplotype is found in 90-95% of patients 
with CD (15), while the HLA-DQ8 haplotype is present in approximately 5% of patients (48). 
However, these haplotypes are present in up to 56% of the general population making them 
necessary but not sufficient for the development of CD (9). 
Environmental factors play a significant role in triggering CD in people who are genetically 
susceptible. Age at first exposure to gluten, elective caesarean section, antibiotic and proton 
pump inhibitor use, history of surgeries and trauma have been suggested as potential 
triggers, however the exact mechanism of how these factors contribute to the development 
of CD is currently unknown (49, 51-53, 221). Many environmental factors associated with the 
development of CD can affect cell function, via gene expression and epigenetic changes.  
Epigenetic modifications, including DNA methylation that can change in response to 
environmental exposure could help to explain how interactions between genes and 
environmental factors combine to trigger disease development. Identification of altered levels 
of methylation associated with disease states, whether predating or following disease, offers 
the potential for discovering new pathways integral to the disease process. Identifying 
changes in DNA methylation profiles in individuals with CD could help discover novel 
genomic regions involved in the onset and development of CD. Many studies have 
investigated the utility of DNA methylation biomarkers for disease screening, diagnosis, and 
management (145, 146). DNA methylation biomarker profiles that differentiate between CD 
and healthy controls could provide an alternative to an invasive intestinal biopsy diagnosis, 
particularly if the biomarkers are present in an accessible tissue such as saliva.  
The aim of this study was to identify DNA methylation differences in the oral methylome from 
saliva samples taken from individuals with managed CD and healthy controls using the 
Illumina Infinium Human Methylation 450K BeadChip array. Additionally, we aimed to 
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validate methylation levels of differentially methylated positions (DMPs) in selected genes 





4.2.1 Participant recruitment and selection criteria 
Recruitment was carried out between April 2014 and August 2016. Individuals were recruited 
from the general population at the 2014, 2015 and 2016 Gluten-Free Expos in Sydney and 
Melbourne, Australia. Individuals forming the pilot cohort were recruited during the earlier 
phase of recruitment. Following the pilot cohort, additional individuals were recruited to form 
the validation cohort. Following written informed consent, individuals were asked questions 
regarding their health and disease status, as previously described (152) (Appendix A). Saliva 
samples were collected from all participants using the Oragene DNA OG500 self-collection 
kits (DNA Genotek, Canada). This study was approved by the Western Sydney University 
Research Ethics Committee (approval number H10513) and was carried out in accordance 
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. 
Individuals in our CD cohort were defined as having CD if they fulfilled the following criteria: 
had been diagnosed with CD via duodenal biopsy by a gastrointestinal specialist; were 
currently on a gluten free diet; and carried at least one HLA-DQ2 or HLA DQ8 haplotype. 
Endoscopy reports were obtained for a subset of CD participants to verify CD histology and 
confirm their CD status. Individuals were classified as non-affected controls if they reported 
not having CD or CD associated symptoms and were not on a gluten-free diet (GFD).  
BMI was analysed as a categorical variable according to World Health Organization 
guidelines (222). Individuals were classified as current, past, or non-smokers, and alcohol 
consumption was categorised into zero, 1-2, and 3-7 standard drinks per week. Participants 
reported if they had ever been clinically diagnosed with cancer, depression, asthma, or any 
of the following autoimmune conditions: Type 1 diabetes mellitus; Autoimmune thyroid 
disease; Rheumatoid arthritis; Lupus; Addison’s disease; Dermatitis herpetiformis; Alopecia, 
Autoimmune Hepatitis, Multiple Sclerosis, Sjogren’s syndrome or Psoriasis. Data from each 
autoimmune condition variable was combined to generate the variable ‘other autoimmune 
conditions’ as the prevalence of each individual condition was low. Individuals with missing 
data or who were current smokers, were excluded. 
Individuals selected for the Illumina Infinium Human Methylation 450K BeadChip array 
satisfied the following criteria, in addition to the above conditions. All individuals were 18 
years or older. CD individuals had to have been diagnosed greater than 2 years ago, had 
been following a strict GFD since diagnosis and were currently symptom free. Non-affected 
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controls reported no family history of CD, and were age and sex matched to the CD group. 
Non-affected controls were also negative for CD using the Simtomax® CD assay, a point-of-
care test that detects IgA and IgG antibodies against deamidated gliadin peptides 
(HealthScreen Solutions, AUS). This is a commercially available screening tool that has a 
negative predictive value of 99.1% (223). 
4.2.2 DNA extraction and HLA genotyping 
Whole saliva was collected from all participants. Saliva (2 ml) was collected using the 
Oragene DNA OG500 self-collection kits (DNA Genotek, Canada). Genomic DNA was 
extracted as per the Oragene prep-IT L2P (DNA Genotek, Canada) protocol, and purified 
using the Qiagen DNA mini kit (Qiagen, Germany) and samples were stored at -20°C until 
analysis. All samples were genotyped for the CD susceptibility haplotypes HLA-DQ2 and 
HLA-DQ8 using TaqMan SNP genotyping assays (Life Technologies, AUS): 
C_11409965_10, C_29315313_10, C_58662585_10, C_29817179_10, and a custom 
designed assay for rs4713586, as previously described (224). Haplotype testing of 
susceptibility haplotypes was performed on both CD and healthy control participants to 
ensure all cases carried either the DQ2 or DQ 8 susceptibility haplotypes. 
4.2.3 Illumina Infinium Human Methylation 450K BeadChip analysis 
Bisulfite converted genomic DNA was hybridized to the Illumina Infinium Human Methylation 
450K BeadChip (Illumina, San Diego, CA). Amplification, hybridization, washing, labelling 
and scanning of the array was performed by the Australian Genome Research Facility 
(AGRF), a fee-for-service provider.  
Raw IDAT files containing signal intensities for each probe were extracted using Illumina 
GenomeStudio software and imported into RStudio using the methylumi and minfi packages. 
Multi-dimensional scaling (MDS) plots of variably methylated probes on the sex 
chromosomes were used to confirm that the predicted sex matches the reported sex for 
each participant. Data quality control and processing steps were conducted using the 
methylumi and wateRmelon packages (155). The pfilter function was used to discard 
samples with a detection p-value > 0.01 in at least 1% samples and/or a bead count less 
than 3 in 5% of samples. Data was normalised using the dasen function (155). Probes 
containing a SNP with minor allele frequency >5% within 5 bp of the single base extension 
site were removed from all analyses based on the SNP annotation data provided by Illumina, 
the Bioconductor package minfi (154), and Chen and colleagues (156). Probes located on 
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sex chromosomes and probes targeting non-CpG sites were also removed from all 
subsequent analysis 
Saliva contains a mixture of different cell types, and cell-type proportions may differ across 
individuals. Surrogate variable analysis using the sva package was used to account for cell 
type heterogeneity within samples and potential batch effects (205), (159). 
4.2.4 Statistical Analysis 
Analyses were performed to test differences in DNA methylation between patients with CD 
and healthy controls at the individual probe level. The pilot cohort consisted of 31 CD 
individuals (12 female) and 28 controls (13 female). Assuming 80% power and α=0.05 per 
marker tested, the study was powered to detect methylation differences between CD and 
non-affected controls of a magnitude of >0.31 (31%). To model the effect of sample-specific 
variables, linear regression for each probe using age, sex and CD status as independent 
variables were performed using the limma package (160). Prior to analysis, β-values were 
log transformed to M-values to improve sensitivity. P-values were adjusted for multiple 
testing according to the false discovery rate (FDR) procedure of Benjamini Hochberg. 
Significantly differentially methylated probes (DMPs) were selected using a cut-off of a |β| 
difference of ≥5% and an adjusted p<0.05. The DMRcate package (163) was then used to 
identify significantly differentially methylated regions (DMRs) (p<0.05, minimum cpg sites = 
2, mean |Δβ| ≥1%) between CD and healthy control samples, as previously described (206).  
4.2.5 Gene Ontology 
Functional annotation analysis and gene ontology (GO) enrichment analysis was performed 
using the missMethyl package (164). The gometh function (prior.prob = TRUE) was used to 
test GO enrichment for significant CpGs. In addition, the gometh function was used to 
perform pathway enrichment analysis based on the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) classification databases to identify significant pathways. Following this, 
the topGO or topKEGG function of the limma package was used to identify the most 
significant GO terms and KEGG pathways.  
In addition, Database for Annotation, Visualization and Integrated Discovery (DAVID version 
6.8) Bioinformatics Resources web-based software tool was used to perform functional 
annotation analysis and GO enrichment analysis. Gene identifiers were uploaded, and 
functional annotation analysis was performed, against the human reference genome, using a 
Benjamini-Hochberg multiple-test adjustment threshold of p<0.05. Pathway enrichment 
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analysis based on the protein annotation through evolutionary relationship and KEGG 
classification databases was used to identify significant pathways.  
4.2.6 Bisulfite Pyrosequencing 
Pyrosequencing assays were performed to confirm the methylation status of CpG sites 
identified by the methylation array. Sites were selected for validation according to β 
difference and functional significance. Sanger sequencing was performed to determine if 
methylation differences observed were due to underlying genomic differences. All 
pyrosequencing and Sanger sequencing was performed by the Australian Genome 
Research Facility.  
4.3. Results 
The genome wide DNA methylation cohort comprised of saliva samples obtained from 31 
CD individuals (12 female) and 28 controls (13 female), matched for sex and age. The mean 
age of individuals with CD was 42 ± 15 years old and healthy controls was 37 ± 14 years old. 
A family history of CD was reported in 39% of the CD group. All individuals were Caucasian 
and no significant differences in BMI, smoking status, or alcohol consumption between the 
two groups was observed. Demographic information is summarised in Table 4.1. All CD 
individuals had been diagnosed at least 2 years prior to recruitment and had been on a strict 
GFD for a minimum of 2 years. All control individuals reported no CD-associated symptoms, 
were consuming a gluten containing diet, did not have family history of CD, and were 
negative for antibodies to deamidated gliadin peptide at time of recruitment. All individuals 
carried at least one HLA-DQ2 or HLA-DQ8 CD susceptibility allele.  
Genome wide DNA methylation was quantified using the Illumina Infinium Human 
Methylation 450K BeadChip (450K array). Following quality control, pre-processing and 
normalisation, 31 CD and 28 control samples were used for analysis. A total of 20 
differentially methylated positions (DMPs) were identified, 9 hypermethylated and 11 
hypomethylated, between CD and controls, and are shown in Table 4.2 (adj. p value <0.05). 
Region analysis of DNA methylation across adjacent probes identified 351 regions, 147 
hypermethylated and 204 hypomethylated, (minimum cpgs = 2, p<0.05) that mapped to 334 
unique annotated genes. The differentially methylated regions (|Δβ|≥5%) are summarised in 
Table 4.3. Functional annotation analysis of these genes did not identify any terms that were 
significantly enriched, however the top 10 terms identified by DAVID included Type 1 
diabetes mellitus (non-adjusted p = 0.02), autoimmune thyroid disease (non-adjusted p = 
0.04) and rheumatoid arthritis (non-adjusted p = 0.03). 
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Table 4.1: Demographic characteristics of initial CD and healthy control cohorts 
Variable Coeliac Control p value 
Alcohol   p = 0.23 
Quit 2 (6.5%) 1 (3.6%0  
Current 14 (45.2%) 23 (82.1%)  
Never 15 (48.4%) 4 (14.3%)  
Drinks per week   p = 0.61 
Zero 17 (54.8%) 7 (25.0%)  
1-2 5 (16.1%) 5 (17.9%)  
3-7 5 (16.1%) 8 (28.6%)  
8-25 4 (12.9%) 8 (28.6%)  
Smoke   p = 0.08 
Quit 8 (25.8%) 10 (35.7%)  
Never 23 (74.2%) 18 (64.3%)  
Other Autoimmune 
Condition 
  p = 0.054 
Yes 14 (45.2%) 5 (17.9%)  
No 17 (54.8%) 23 (82.1%)  
Sex   p = 0.64 
Male 12 (38.7%) 13 (46.4%)  
Female 19 (61.3%) 15 (53.6%)  
BMI   p = 0.86 
Underweight (<18.5) 1 (3.2%) 0 (0%)  
Healthy (18.5-24.99) 13 (41.9%) 15 (53.6%)  
Overweight (25-29.99) 11 (35.5%) 9 (32.1%)  




Table 4.2: Differentially methylation positions identified between individuals with CD 
and healthy controls 






Hypomethylated      
chr19:14142585 cg06860352 IL27RA 5'UTR p < 0.05 -0.01 
chr8:2060933 cg05570806 MYOM2 Body p < 0.05 -0.01 
chr8:128748337 cg03076047 MYC 5'UTR p < 0.05 -0.02 
chr7:97923044 cg27013914 BAIAP2L1 Body p < 0.05 -0.02 
chr2:11864427 cg15380473   p < 0.05 -0.02 
chr19:649301 cg18811158 RNF126 Body p < 0.05 -0.02 
chr17:45907760 cg12380854 LRRC46;MRPL10 TSS1500 p < 0.05 -0.02 
chr10:135141628 cg11126081 CALY Body p < 0.05 -0.03 
chr11:33334443 cg26400421 HIPK3 Body p < 0.05 -0.03 
chr5:156516798 cg19063654 HAVCR2 Body p < 0.05 -0.04 
chr16:6976709 cg16716449 A2BP1 5'UTR p < 0.05 -0.10 
Hypermethylated 
     
chr12:30251537 cg09151187   p < 0.05 0.03 
chr14:68283333 cg12952552 ZFYVE26 TSS1500 p < 0.05 0.01 
chr17:61920550 cg04367190 SMARCD2 TSS1500 p < 0.05 0.01 
chr6:7389895 cg05371005 CAGE1;RIOK1 5’UTR p < 0.05 0.01 
chr6:26027625 cg12474759 HIST1H4B TSS1500 p < 0.05 0.01 
chr3:112738652 cg05582165 C3orf17 TSS1500 p < 0.05 0.01 
chr11:14542136 cg12352359 PSMA1 TSS1500 p < 0.05 0.01 
chr10:81741832 cg18762849   p < 0.05 0.01 
chr13:52586133 cg18796523 ALG11;ATP7B TSS1500 p < 0.05 0.01 
      
TSS = 200-1500 bases upstream of transcription start site, 5’UTR = 5’ – untranslated region 
upstream from initiation codon, Body = body of gene. Positive Δβ values indicate 
hypermethylation in individuals with CD; negative Δβ values indicate hypomethylation in 














chr6:33053576-33054001 5 HLA-DPB1  -0.08 
chr2:113190072-113190197 2 RGPD8  -0.07 
chr2:130794753-130795678 4 FAR2P1  -0.06 
chr20:623089-623421 4 SRXN1  -0.06 
chr7:100343083-100343110 2 ZAN  -0.05 
chr6:31275148-31276797 24 HLA-B  -0.05 
chr15:29034942-29034950 2 PDCD6IPP2  -0.05 




chr1:246667857-246668601 2 SMYD3  0.13 
chr17:6557720-6558815 6 MIR4520-2  0.09 
chr15:41098188-41100308 14 ZFYVE19  0.07 
chr3:196705629-196705898 5 PIGZ  0.07 
chr6:32632694-32633163 8 HLA-DQB1  0.06 
chr6:25882328-25882590 5 SLC17A3  0.05 
chr11:288301-288305 2 ATHL1  0.05 
chr5:77146796-77147141 3 TBCA  0.05 
chr14:24779400-24780926 14 LTB4R2  0.05 
     
 
CpG sites within the SET and MYND domain containing 3 (SMYD3) gene, the solute carrier 
family 17 member 3 (SLC17A3) gene, the zinc finger FYVE-type containing 19 (ZFYVE19) 
gene, the major histocompatibility complex, class II, DP beta 1 (HLADPB1) gene and the 
major histocompatibility complex class II DQ beta I (HALDQB1) were selected for further 
investigation based on the magnitude of mean DNA methylation difference across all CpG 




Figure 4.1: Top ranked differentially methylated regions of interest between CD and controls on 450k analysis. 




Figure 4.2: Top significantly differentially methylated CpG sites on 450k microarray analysis (n = 59) between CD and controls. 
Beeswarm plots indicate individual methylation levels for each participant at each of the top significantly differentially methylated CpG sites on 
450k microarray analysis. The mean Δβ, median and interquartile ranges of the CD and control cohorts is shown.   
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The largest methylation difference was observed at cg04798314 within the SMYD3 gene. 
Methylation patterns at this site suggested the presence of an underlying DNA variant 
(Figure 4.2). DNA sequencing of the cg04798314 site identified an insertion of a thymine (T) 
which disrupted the CpG site. This is a known variant, rs201044038, with an unknown 
population frequency and as such was not excluded during the initial methylation pre-
processing which removed probes within known variants with a minor allele frequency 
greater than 1%. Genotyping within the pilot cohort found individuals with CD were 
significantly less likely to carry a copy of the rs201044038 variant when compared to control 
individuals (57% vs 96%, p=0.002). Individuals who were heterozygous or homozygous for 
the rs246668601 variant had reduced or no methylation at this site which explains the 
difference in methylation seen between groups. 
Similarly, methylation patterns at the cg14373797 site within the HLADPB1 gene indicated 
the presence of an underlying DNA variant which impacted DNA methylation (Figure 4.2). 
The HLADPB1 gene is highly polymorphic and contains known DNA variants at and around 
the cg14373797 site. One base downstream from cg14373797 is a known variant, rs9276, 
which directly disrupts the CpG site leading to a loss of methylation. Genotyping of this 
variant in the cohort identified a significant difference in the frequency of the variant in CD 
and controls (4.3% and 47.8% of CD were homozygous and heterozygous respectively for 
the variant while 95.7% of healthy controls did not carry the variant (p<0.001). 
Bisulfite pyrosequencing was used to validate 6 CpG sites within the HLADQB1, SLC17A3 
and ZFYVE19 genes. Three sites within the SLC17A3 gene were confirmed as being 
differentially methylated between CD and control individuals (Figure 4.3A). No significant 
methylation differences were confirmed on pyrosequencing for the two sites within ZFYVE19 
gene, cg13045913 (6.7% vs 4.9%, p = 0.17) and cg25498107 (20.3% vs 16.3%, p = 0.21), 
and the one site within HLADQB1, cg1098291 (3.3% vs 4.7%, p = 0.11).   
We subsequently recruited an additional n=227 individuals, 154 CD and 73 controls to 
determine whether the methylation differences in SLC17A3 could be replicated in a larger 
dataset. Within the larger dataset, the mean age of individuals with CD was 45 ± 15 years 
old and healthy controls was 41 ± 15 years old. Individuals with CD were significantly more 
likely to report having been diagnosed with another autoimmune condition (p = 0.01). 
Individuals with CD were significantly more likely to be female (p = 0.002). No significant 
difference in age, BMI, lifestyle factors or family history of CD was observed between CD 
and controls in this cohort.  
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Significant differences in methylation was observed for all three cg sites within the SLC17A3 
region between CD and control individuals within the second cohort (n = 227) following 
pyrosequencing (Figure 4.3B). Interestingly, the direction of the methylation differences 
between the cohorts was in the opposite direction to that seen in the initial cohort, with 
methylation at all three sites lower in CD compared with controls in the larger cohort.  
No significant difference was observed in the frequency of the SYMD3 variant, rs201044038, 
in the validation cohort between individuals with CD and healthy controls (71.4% vs 76.7%, p 
= 0.40). Genotyping of the rs9276 variant in the HLADPB1 gene showed a significant 
difference in the frequency of the variant within the validation cohort, with 2.6% and 30.5% of 
CD individuals homozygous and heterozygous respectively for the variant, while 83.6% of 





Figure 4.3: Significantly differentially methylation CpG sites validated by pyrosequencing.A: Bisulfite pyrosequencing within the 
SLC17A3 gene confirmed significant methylation differences at three CpG sites between CD and controls in the initial cohort (n = 46). B: 
Bisulfite pyrosequencing on the same three CpG sites within the SLC17A3 gene showed significant methylation differences between CD and 




CD is a chronic autoimmune condition that can be challenging for clinicians to recognise and 
diagnose. It has a known genetic component with CD individuals carrying either the HLA-
DQ2 or HLA-DQ8 haplotype. However, these haplotypes are present in up to 56% of the 
general population making them necessary but not sufficient for the development of CD (9). 
Environmental factors have been reported to play a role in triggering CD in genetically 
susceptible individuals however the exact mechanism of how they contribute to disease 
development is unknown. Changes in DNA methylation may help to explain how 
environmental triggers can induce disease development. To our knowledge this is the first 
study to investigate DNA methylation differences in oral mucosa cells from saliva in 
individuals with managed CD and healthy controls. Our preliminary findings identified DNA 
methylation differences near the SLC17A3 gene.  
Individuals with CD are known to have a higher prevalence of other autoimmune disorders 
when compared to the general population (25), and studies have reported that approximately 
35% of patients with CD will also have an additional autoimmune condition (26). This was 
reflected in the validation cohort (n=227), where individuals with CD were significantly more 
likely to report having another autoimmune condition compared to the healthy controls (37% 
vs 26%, p=0.01). Type 1 diabetes mellitus, autoimmune thyroid disease and rheumatoid 
arthritis were identified during functional enrichment analysis of genes that mapped to 
differentially methylated regions. Despite not being significantly enriched, this result was 
unsurprising given the shared risk variants that exists across CD (44), type 1 diabetes (89), 
rheumatoid arthritis (86) and Crohn’s disease (90) where the HLA region features 
prominently (225), indicating that the mechanisms responsible for disease development may 
be common across the conditions. 
Hypermethylation of CpG sites upstream of the SLC17A3 gene was observed in CD 
individuals compared to healthy controls in the initial pilot cohort. However, validation of 
these three CpG sites in a secondary cohort found hypomethylation in CD individuals when 
compared to healthy controls at all three sites. The SLC17A3 gene spans the region of 
chr6:25,845,610-25,874,471. The three CpG sites are located approximately 8,000bp 
upstream of the genomic region.  
The SLC17A3 gene encodes a voltage-driven transporter protein that is involved in the 
elimination of urate and organic anions from the blood, and forms part of the extended major 
histocompatibility complex region. Elevated uric acid levels are markers of oxidative stress 
and inflammation, where uric acid, an antioxidant is produced in response to inflammation 
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and oxidative stress (226). Increased uric acid levels are associated with type 1 diabetes 
(227), gout (228), and rheumatoid arthritis (229), while reduced uric acid levels have been 
observed in multiple sclerosis (230) and pemphigus vulgaris, an autoimmune disorder 
characterised by blistering of the mucous membranes (231).  
The small intestine is a major site for uric acid production (232), and individuals with CD 
have elevated uric acid serum levels when compared to healthy controls which may reflect 
the inflammation and oxidative stress that is characteristic of CD even when following a GFD 
(233). The opposing direction of methylation differences between the initial cohort and the 
secondary cohort, hyper vs hypomethylation of the sites in CD individuals highlight the 
importance of validating findings, as well as the limitations of using smaller sample sizes. A 
similarly designed study investigating methylation as a diagnostic biomarker in Barrett’s 
oesophagus, utilised comparable sample numbers in both their pilot and validation cohorts 
(234). They used a total of 20 cases and 10 controls for pilot investigations and then 
selected genes were investigated in validation cohorts comprising of 149 cases and 129 
controls. This study was successful in achieving significant methylation differences in genes 
which could be used as potential diagnostic biomarkers. In the context of this study, further 
testing in another cohort could help to elucidate whether methylation differences at these 
sites are present and in what direction that difference is. Alternatively, investigation of the 
next top significant sites identified on 450k array in the pilot cohort may yield different sites of 
interest. 
The largest methylation difference was observed at cg04798314 within the SMYD3 (Homo 
sapiens SET and MYND domain containing 3) gene which encodes a histone 
methyltransferase. Histone methylation events regulate transcriptional activity through the 
modification of chromatin structure by enabling RNA polymerase II and transcription factors 
to access gene promoter regions. SYMD3 is important in histone lysine methylation activity, 
specifically methylation of lysine 4 of histone H3 (H3K4) which is associated with 
transcriptional activation (235). Altered expression of SYMD3 has been associated with 
several types of cancer (236). Overexpression of SMYD3 in gastric cancer has been 
associated with poorer prognosis (237), while loss of SMYD3 can suppress gastric cancer 
cell migration and proliferation (238). Emerging evidence suggests the SMYD family of 
proteins have a role in immunity. SMYD3 is an epigenetic mediator of the transcription factor 
fork-head box P3 (FOXP3), which is involved in the development and function of regulatory 
T cells. FOXP3 expressing T regulatory cells are critical for self-tolerance. Reduced 
expression of FOXP3 which disrupts T regulatory cell development, has been associated 
with type 1 diabetes mellitus (239) and systemic lupus erythematosus (240).  
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Within SYMD3 the thymine insertion variant rs201044038 disrupts the CpG site at 
cg04798314 leading to a loss of methylation. CD individuals in the pilot cohort were less 
likely to carry a copy of rs201044038 when compare to controls (57% vs 96%, p=0.002) and 
as a result were more likely to have higher levels of methylation at this site. However, this 
finding was not validated in the validation cohort. The rs201044038 variant is located within 
intron 1 of SYMD3 and is it unknown whether the variant has functional significance or 
affects expression. DNA methylation is generally associated with reduced gene expression, 
and reduced SYMD3 expression is associated with autoimmune disease via dysregulation of 
T regulatory cells. However, given the location of the variant in intron 1 it is unknown 
whether increased methylation at this site would impact SMYD3 expression or contribute to 
CD.  
Similarly, a non-synonymous missense variant was observed at the cg14373797 site, 
located within an exon of the HLADPB1 gene. The rs9276 variant located one base 
downstream from the cg14373797 CpG site disrupts the CpG site causing a loss in 
methylation. In this study, rs9276 was present in <5% of healthy controls which is in line with 
European population frequency data, interestingly, 52% of our CD cohort carried the variant. 
The clinical significance of the variant is currently unknown, and further investigation in 
significantly larger CD cohort is required to determine whether the variant is associated with 
CD.  
Limitations of the study include the small size of the pilot cohort used for the methylation 
arrays which may have increased the likelihood of false positive results, as evident in the 
differing methylation results observed between the pilot and validation cohort for the 
SLC17A3 gene. This study used self-reported data which can be subject to recall bias. Self-
reporting of CD status may have led to false-positive CD classification. However, the CD 
cohort was restricted to individuals who had been diagnosed via an intestinal biopsy by a 
gastrointestinal specialist. Endoscopy reports for a subset of CD participants, including the 
CD individuals in the pilot cohort, were also obtained to verify CD histology and confirm 
diagnosis to minimise the chance of misclassification. The healthy control individuals within 
the pilot cohort while negative for CD serology (via the Simtomax® point of care CD assay) 
and associated symptoms at recruitment carry the HLADQ2 or HLADQ8 susceptibility 
haplotypes and may develop CD in later life. In the validation cohort, false negative CD 
classification for controls is also possible given the high prevalence of CD (1 in 70) in the 
general population and that individuals with CD can be asymptomatic. 
Perhaps the largest factor to influence the absence of large DNA methylation differences 
observed in our study was that all individuals in our CD cohort were individuals with treated 
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CD. That is they had been diagnosed at least 2 years prior, were on a strict gluten free diet, 
and reported being symptom free. Epigenetic profiles can change over time and during 
disease progression. It is possible that DNA methylation profiles will differ between 
individuals with active or untreated CD compared with individuals on a strict gluten free diet. 
In individuals with CD, initiation of a gluten free diet reduces intestinal inflammation and 
enables mucosal healing and repair. It is possible that any significant DNA methylation 
changes that occurred as a result of disease have been diminished or reversed with 
appropriate management and time. The rationale for using CD individuals without active 
disease was to identify DNA methylation markers that were unique to CD regardless of 
disease state. We had hypothesised that any DNA methylation changes that occurred in the 
development of CD would be permanently maintained given that a CD diagnosis is lifelong. 
Future studies comparing DNA methylation profiles in individuals with active/untreated CD vs 
gluten free diet treated CD vs healthy controls could help to differentiate DNA methylation 
changes that are disease specific and/or state specific.  
4.5. Conclusion 
To our knowledge this is the first study to compare DNA methylation profiles CD individuals 
and healthy controls. Our study identified a potentially novel epigenetic target that may be 
associated with CD development in the region of SLC17A3. Further investigation is required 
to validate this result. The regions identified in this study support the notion that autoimmune 
conditions have overlapping and shared mechanisms, as many have been associated with 
other autoimmune conditions including type 1 diabetes, rheumatoid arthritis and systemic 
lupus erythematosus. Further work in individuals newly diagnosed with CD is needed to 













Coeliac disease (CD) is a highly prevalent chronic autoimmune disease affecting 
approximately 1% of the population worldwide (1). It has a diverse clinical heterogeneity, 
ranging from asymptomatic to severe, with symptoms including diarrhoea, weight loss, 
anaemia and malabsorption (3). The only treatment is a life-long avoidance of gluten 
containing foods. Diagnosis includes blood serology and an invasive gastroscopy procedure 
to confirm CD histology. During this process an individual must be actively consuming gluten 
in order to gain an accurate diagnosis, which can be problematic given the popularity of 
gluten-free diets (GFDs). It is currently estimated that up to 80% of Australians with CD 
remain undiagnosed due to the variability of symptoms and the nature of the diagnostic 
process (10). Alternative screening tests that avoid the need for active gluten consumption 
and are non-invasive would be beneficial.  
Individuals with a family history of CD are at a higher risk of developing disease indicating a 
genetic component. Genetic testing for the CD susceptibility haplotypes HLA-DQ2 or HLA-
DQ8 are useful for identifying individuals who will not develop CD however as 56% of the 
Australian general population carry these haplotypes, their use is limited (9). In recent years, 
research into the involvement of DNA methylation in disease development and management 
has been investigated in multiple disease settings, and differences in DNA methylation 
profiles in inflammatory intestinal diseases have been identified.  
The overall aim of this thesis was to investigate DNA methylation profiles associated with 
CD. To achieve this, the feasibility of saliva and the oral mucosa as an alternative tissue 
source for DNA methylation studies in intestinal disorders was first examined (Chapter 2). 
The influence of gluten on salivary DNA methylation profiles and the saliva microbiome in 
healthy individuals was then characterised (Chapter 3). Finally, DNA methylation profiles in 
saliva were compared between CD and non-CD individuals to identify whether epigenetic 
mechanisms are involved in the development of CD (Chapter 4). This chapter will 
summarise the main findings from this thesis and suggest areas of future research to build 
on the results presented here. 
5.1. Saliva as a DNA source for DNA methylation studies 
Previous DNA methylation studies in inflammatory intestinal conditions utilised intestinal 
mucosal tissue or peripheral mononuclear blood for their genomic DNA. The collection of 
these samples is invasive, carries the risk of complications, and requires trained personnel, 
which for large-scale research studies can be problematic. Saliva has been shown to yield 
DNA of sufficient quantity and quality for genetic and epigenetic studies (149). In DNA 
methylation studies saliva has been shown to be a viable surrogate for less accessible 
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tissues including brain (134), lung/bronchial epithelium (135), and peripheral blood 
mononuclear cells (133). DNA methylation profiles in saliva and intestinal mucosa within an 
individual were compared to determine the feasibility of saliva in DNA methylation research 
in intestinal conditions. This study found that methylation profiles generated from saliva were 
high quality and suitable for downstream analysis. DNA methylation profiles were positively 
correlated between saliva and intestinal mucosal tissues within an individual (intra-
individual), and the differentially methylated regions that were identified mapped to genes 
with tissue specific functions.  
Interestingly, methylation profiles in saliva exhibited greater variability between individuals 
(inter-individual), compared with intestinal mucosal profiles. Two distinct clusters, based on 
presence and absence of CD, were observed in the DNA methylation profiles from saliva, 
which was not observed in the intestinal mucosal samples. We hypothesise that the 
groupings may be the result of differences in disease status and/or diet and would indicate 
that not only is saliva a suitable alternative for DNA methylation research in intestinal 
conditions – it is also a potentially more informative tissue source with regard to DNA 
methylation.  
5.2. The effect of gluten on DNA methylation and the saliva microbiome 
Diet has been shown to influence epigenetic changes (214). Additionally the gut microbiome 
has been shown to induce DNA methylation via the production of metabolites used in 
epigenetic modifications (172). The influence of diet on the microbiome has been well 
established. Diet is understood to play a significant role in shaping the microbiome with 
studies showing that alterations to dietary habits can induce alterations in microbiome 
composition (190, 241). In the context of short-term gluten removal on the gut microbiome, 
previous studies have reported changes in microbial populations (66, 176), which would 
indicate that diet-induced microbiome alternations could induce changes in DNA methylation 
profiles.  
Clustering in DNA methylation profiles of individuals with CD observed in Chapter 2 may be 
the result of differences in disease status, diet or microbiome. To date, no studies have 
reported the effect of gluten removal on the saliva microbiome, and whether changes to the 
saliva microbiome impact saliva DNA methylation profiles. Chapter 3 describes how the 
influence of short-term gluten removal on the saliva microbiome and saliva DNA methylation 
profiles was investigated. This arm of the study utilised healthy non-CD individuals in order 
to eliminate any effect that CD may have on DNA methylation and the microbiome. 
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No variations in microbial diversity or alterations in microbial species composition or 
abundance were observed following a GFD. Similarly, no difference in saliva DNA 
methylation profiles within healthy individuals following a short-term GFD was observed, 
which was not surprising given the absence of change in saliva microbiome profiles before 
and after the uptake of a GFD. This suggests that a GFD does not appear to impact health in 
healthy individuals with regard to their saliva microbiome or saliva DNA methylome in the 
short-term.  
Previous studies have demonstrated alterations in faecal and duodenal microbiome 
compositions in individuals with active CD compared with healthy individuals (64, 242). 
Future research investigating the saliva microbiome of individuals with active CD and treated 
CD are needed to determine if similar alterations are reflected in the oral mucosa.  
5.3. DNA methylation profiles in CD 
Environmental factors associated with the development of CD can affect gene expression 
and cell function, via epigenetic changes. DNA methylation changes may be the potential 
mechanism for which interactions between genetic and environmental factors trigger 
development of disease. Genome wide association studies have reported significant genetic 
overlap between CD and other autoimmune conditions including type 1 diabetes (89), 
rheumatoid arthritis (86) and Crohn’s disease (90), which would suggest common pathways 
and mechanisms are responsible for disease development. DNA methylation biomarkers are 
currently used to diagnose, inform treatment and stratify the risk of developing disease. 
Studies investigating the utility of DNA methylation biomarkers for disease screening, 
diagnosis, and management have identified DNA methylation changes associated with 
disease state, which may point to new pathways integral to the disease process (145, 146).  
A potentially novel epigenetic target that may be associated with CD development was 
identified in the region of the SLC17A3 gene. Novel susceptibility loci in the SLC17A3 gene, 
which is involved in the elimination of urate from the blood, have previously been identified in 
dyslipidemia and ischemic shock (243, 244). No known associations have been made with 
the region identified in this study, however further investigation due to the conflicting results 




5.4. Study limitations 
Self-reported data which included diagnosis of CD was utilised for many aspects of this 
thesis. The method of recruitment, mainly through the Sydney and Melbourne Gluten-free 
Expos meant that self-reported data collection was the most efficient way to obtain adequate 
participant numbers within that setting. In total 1054 individuals were recruited over the span 
of the study (2015 to 2017). These individuals comprised of people with CD, their affected 
and non-affected family members, non-CD individuals on a GFD, and healthy controls. Self-
reported data is subject to recall bias which can impact accuracy of CD status however a 
strict criterion was used to classify and define participants. To minimise the chance of false-
positive and/or self-diagnosed CD, CD status was restricted to individuals who reported 
being diagnosed via an intestinal biopsy by a gastrointestinal specialist. Considering the 
invasive nature of the gastroscopy procedure it is likely that recall of this procedure will be 
more accurate than reporting history of a previous illness or infection. Another factor in our 
favour was that a significant number of CD individuals recruited at the Gluten Free Expos 
were members of the Coeliac Society of Australia. Membership requires a formal diagnosis 
of CD, and until recently confirmation via the provision of the gastroenterologist’s report. 
Furthermore, for the CD participants used in Chapter 2, and the participants in the pilot 
cohort in Chapter 4, endoscopy reports were obtained to verify CD histology and confirm 
diagnosis. From a resource perspective it was not feasible to obtain medical records to 
confirm disease status for all CD individuals recruited. Future recruitment opportunities could 
focus on selecting specific sites such as a gastroenterologist’s clinic in order to maximise the 
reliability of CD diagnosis reported.  
All individuals classified as CD in this study reported currently being on a strict GFD for a 
minimum period of 2 years and reported no current gastrointestinal symptoms. Due to the 
self-reporting nature of this data there is a potential that some individuals may have had 
recent minimal inadvertent gluten exposure or had ongoing asymptomatic disease. It was 
not feasible to test all CD individuals using the Simtomax® CD assay to determine whether 
they had any elevated tTG-IgA and elevated deamidated gliadin peptide-IgG antibodies 
present. Non-CD control individuals were defined if they reported not being on a GFD and 
not having any gastrointestinal symptoms characteristic of CD. For the pilot cohort in 
Chapter 4, further restrictions including no family history of CD and being negative for CD 
antibodies using the Simtomax® CD assay, a blood fingerpick point of care test. As with the 
CD cohort it was not feasible to test all non-CD control individuals in this manner, particularly 
the non-CD individuals used in the validation cohort in Chapter 4. As a result, there is a 
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small possibility of false negative CD classification given the high prevalence of CD (1 in 70) 
in the general population and that individuals with CD can be asymptomatic (9). 
The small sample sizes used in Chapter 2 and Chapter 3 increases the likelihood of Type II 
errors where small but significant alterations in microbial diversity or methylation profiles may 
have been missed. By increasing the sample size in both these studies the likelihood of 
Type II errors would be minimised. The invasive nature of intestinal biopsy sample collection 
and strict criterion of suitable patients available limited our ability to recruit large numbers of 
individuals in Chapter 2. However, a similar designed study, investigating DNA methylation 
of mucosal biopsy samples in ulcerative colitis utilised a comparably small sample size 
(n=10 cases, n=11 controls) and identified methylation differences that could be replicated in 
a larger cohort (245). In Chapter 3, the out-of-pocket expenses associated with a strict GFD, 
and the need to alter or substitute a significant part of the diet (no beer, GF bread and pasta) 
was unappealing for many people which also limited our recruitment numbers. Similarly 
designed studies, investigating the impact of GFDs on the microbiome have been conducted 
in small sample sizes (n=10 or n=21) and were successful in observing significant 
differences between baseline and diet samples (66, 176). In Chapter 4, the opposite 
direction of methylation differences between the initial and validation cohorts observed 
shows the limitation of using smaller sample sizes. Further testing in a much larger cohort 
would help to elucidate whether methylation differences between the disease groups are 
present. The high cost of DNA methylation and microbiome technologies, in particular the 
Illumina Infinium Human Methylation 450K BeadChip array and the subsequent 
pyrosequencing, also limited the ability to analyse large numbers of samples.  
In Chapter 3, individuals underwent a short-term GFD to assess any changes to methylation 
or microbiome profiles. All individuals were educated on typical foods that contain gluten, 
how to accurately read food labels to prevent accidental gluten consumption, and GF 
alternatives that could be used as a substitute to maintain their regular eating habits, before 
commencing the GFD. Following the GFD, individuals were asked about any significant 
changes to their dietary habits; however, to improve the reliability of this information, future 
participants could complete a food diary and have the GFD evaluated by an accredited 
dietitian. This would help to confirm adherence to the GFD and establish whether 
macronutrient and energy consumption were being maintained throughout the study period. 
In this study samples were only collected before the commencement of a GFD and at the 
conclusion of the diet period. Expanding the number of intervals for sample collection to 
during the diet period and then at intervals after the conclusion of the GFD could be 
informative to determine whether DNA methylation and microbiome profiles remain at 
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baseline levels if an individual chooses to recommence a regular diet. The information 
gathered from a longitudinal study on the effect of diet on the microbiome would help to 
pinpoint both how long an individual would need to be on a GFD before seeing microbial 
differences, as well as determining how long it would take for an individual to return to 
baseline measurements after resuming a regular diet. 
Chapter 4 compared DNA methylation profiles between individuals with CD to healthy 
controls. The absence of any large DNA methylation differences being observed may be due 
to the fact that all individuals with CD had been diagnosed at least 2 years prior, were 
following a strict GFD, and reported being symptom free. In a similarly designed study 
investigating Crohn’s disease paediatric blood samples were analysed for 164 cases and 74 
controls (246). A total of 1182 significant CpG sites were identified as being associated with 
Crohn’s disease at the point of diagnosis, before treatment was started. Following treatment, 
most of the methylation changes observed, disappeared and more closely resembled that of 
controls, indicating that the majority of CpG methylation changes identified were a result of 
the inflammatory features of the disease. This indicates that methylation changes associated 
with disease are reversible with treatment. It is possible that DNA methylation profiles will 
differ between individuals with active or untreated CD compared with treated CD individuals. 
The rationale for using treated CD individuals as opposed to those with active disease was 
to identify DNA methylation markers that were unique to CD regardless of disease state. It 
was hypothesised that DNA methylation changes as a result of disease would be 
permanently maintained given that CD is a lifelong disease, however future investigations in 
individuals with active, or untreated CD, may identify differences in DNA methylation profiles 
and show that with appropriate management and given time for inflammation associated 
damage to heal, DNA methylation may revert to pre-disease levels. Investigations of a 
longitudinal nature to compare methylation profiles within the same individual at an active 
disease point that is at diagnosis before treatment has started, and then at specific time 
intervals after treatment has commenced would help to determine if DNA methylation levels 
can be associated with inflammation induced damage. Previous studies investigating 
methylation levels in IBD have identified significant differences in epithelial cells taken from 
patients with ulcerative colitis at both inflamed and non-inflamed sites of the colon (247). 
Investigations were not conducted into whether these differences subsided once healing of 
the inflammation occurred.  
CD specific DNA methylation biomarkers were not able to be identified in this study however 
DNA methylation biomarkers are currently utilised to diagnose, inform treatment options and 
stratify the risk of developing disease for other diseases. The SEPT9 gene methylation 
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assay was the first FDA-approved blood assay for colorectal cancer screening (248). The 
introduction of this early screening biomarker test has prolonged patients’ lives and reduced 
mortality. The assay works on the basis that aberrant methylation is observed at the 
promoter region of the SEPT9 gene and released from colorectal cancer cells into peripheral 
blood. The risk of colorectal cancer can be determined by detecting the degree of DNA 
methylation of the promoter region. This assay has benefited the average-risk population 
who refuse invasive screening tests, but will undergo a simple blood-based test (248). The 
SEPT9 methylation array is an example of an individual point methylation array, however 
panels of multiple methylation sites are important for disease diagnosis in lung and breast 
cancer. A signature of hypermethylation across four genes has been identified in lung cancer 
(249) while studies into breast cancer have shown that analysis of individual genes is not 
sufficient to detect breast cancer and  multi-gene panel assaying are needed to improve 
sensitivity and specificity of screening (250). The presence of these DNA methylation 
biomarkers allows for earlier diagnosis, earlier treatment and monitoring of disease 
progression without the need for invasive procedures.  
Genome-wide biomarker assays using whole-genome bisulfite sequencing are not clinically 
feasible assays due to their cumbersome nature and are too expensive for routine clinical 
diagnostics. Instead absolute DNA methylation assays, including pyrosequencing, would be 
the method of choice for developing epigenetic biomarkers (251). Saliva offers key 
advantages for DNA methylation arrays; as it is easy to collect with few constraints on 
storage and processing. High quality methylation profiles have been generated from saliva 
(148). Developing an absolute DNA methylation biomarker assay using saliva samples that 
is independent of gluten consumption for CD would be beneficial. 
The non-CD individuals within the pilot cohort, while negative for CD serology and 
associated symptoms, carried either the HLA-DQ2 or HLA-DQ8 susceptibility haplotypes 
and therefore may develop CD later in life. The absence of the HLA-DQ2 or HLA-DQ8 gene 
almost always excludes CD with a negative predictive value of more than 99% (78, 79) so 
the rationale to genotype match in our pilot cohort was because individuals without these 
genes are unlikely to develop disease. Individuals were additionally age and sex matched, 
as well as, limiting individuals with specific other autoimmune diseases and excluding 
individuals that were current smokers to make the cohorts as homogenous as possible.  
5.5. Future research 
Chapter 2 showed that methylation profiles were comparable between saliva and intestinal 
samples in individuals with treated CD and non-CD individuals. Further comparisons 
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between saliva and intestinal samples in individuals with active CD would be interesting to 
see whether the inflammation damage caused by disease in the intestinal mucosa would 
affect methylation profiles and whether this would be reflected in the oral mucosa as well.  
In Chapter 3, a short-term GFD did not change DNA methylation profiles nor the saliva 
microbiome in healthy individuals. A period of 6 weeks was used for this study, however a 
GFD over a longer period of time, would help to establish whether the shorter timeframe was 
long enough to see any epigenetic impacts caused by the diet. Investigating the impact of a 
GFD on individuals with disease is also warranted, however the ability to determine whether 
any changes seen are a result of the diet or a result of disease healing would be difficult. 
Currently, individuals are required to be actively consuming gluten during the diagnostic 
process in order to show elevated levels of CD specific antibodies and to show intestinal 
histological changes. If DNA methylation biomarkers were utilised for disease screening, 
knowing that a short-term GFD does not cause any significant changes to DNA methylation 
profiles, could negate the need for individuals to be actively consuming gluten to be 
diagnosed with CD. Future research that could establish DNA methylation biomarkers which 
differentiate between people with and without CD, irrespective of GFD status would be 
beneficial as it would allow clinicians to advise patients currently suffering from what they 
believe is CD to adopt a GFD immediately to help alleviate symptoms while undergoing the 
testing phase.   
The microbiome is also known to be affected by disease. Future work comparing saliva 
microbial profiles of individuals with and without CD would be interesting. Furthermore, 
comparisons between the intestinal mucosa and the oral mucosa in individuals with active 
CD, with treated CD and healthy controls would also be valuable to determine how 
environmental exposures and disease-status affect the microbiome composition at these 
sites. As mentioned earlier, by collecting samples at multiple time points during the diet 
period and multiple time points after the conclusion of the diet, would also be beneficial.  
In Chapter 4, we had hypothesised that any DNA methylation changes that occurred during 
the development of CD would be permanently maintained given that a CD diagnosis is 
lifelong. The rationale for using CD individuals without active disease was to identify DNA 
methylation markers that were unique to CD regardless of disease state. No consistent DNA 
methylation regions were identified. Given that epigenetic profiles can change over time and 
during disease progression future studies could focus on comparing DNA methylation 
profiles in individuals with active/untreated CD with GFD treated CD, and with healthy 
controls. This could help to identify any DNA methylation changes that are disease specific 
and/or disease-state specific. To establish a set of DNA methylation changes that are 
79 
 
disease specific, future recruitment would need to be expanded to include individuals with 
active disease. That is, individuals at the point of diagnosis, whilst they are unwell and 
suffering from the effects of disease. Longitudinal follow up and sample collections from 
these individuals following commencement of a GFD at regular intervals; for example; 3 
months, 6 months, 12 months and 24 months would provide a snapshot of DNA methylation 
profiles that coincide with healing stages, symptom relief, reduction of CD serology and 
intestinal mucosal healing. Recruitment of individuals at diagnosis has commenced and 
follow up of these individuals will occur past the scope of this thesis.   
Longitudinal follow up of family members, particularly first-degree relatives who carry the CD 
susceptibility haplotypes and are at risk of developing CD would also be beneficial. Again, 
this would provide the means to investigate potential DNA methylation changes as a result of 
disease development. Following these individuals as they progress from non-CD, to CD and 
then GFD treated CD would be a worthwhile endeavour to track potential DNA methylation 
changes across the different stages.  
Epigenetic changes, in particular DNA methylation, can provide a better framework of how 
disease is triggered and what environmental and biological processes contribute to the 
development of disease. Recruitment of individuals with active CD and their continued 
monitoring throughout the stages of disease from pre-disease, to active disease and finally 
to treated disease states, is needed to determine the contribution of DNA methylation in the 
development of CD. If DNA methylation changes can be established between individuals 
with both active and treated CD compared to healthy controls, independent of gluten 
consumption and reflected in both the intestinal mucosa and saliva, DNA methylation 
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Appendix A: Genetic Basis of Coeliac Disease Data Collection Sheet 
GENERAL INFORMATION 
1. What is your sex?   Male  Female 
 
2. What is your date of birth? (dd/mm/yy) 
 
 / /  
 




4. What is your postcode?  
 
5. What is the primary language spoken at home? 
  English   
  Other     
 
6. What is the highest level of education/qualification you have completed? 
 Year 10 or equivalent  
 Higher School Certificate or equivalent  
 TAFE diploma  
 Undergraduate degree  
 Postgraduate degree  
 None of the Above  
 
7. What is your height (cm)   
 




COELIAC DISEASE DIAGNOSIS  
9. Have you been diagnosed with coeliac disease by a doctor?  Yes  No 
 
If ‘No’ please proceed to question 14 
 
10. On what date were you diagnosed with coeliac disease? 
(approximate month/year)   
 
11. What method/s was used to diagnose your coeliac disease? (tick all that apply) 
 Small bowel biopsy  
 HLA gene test  
 Blood test for elevated antibodies  
 Unknown  
 Other _______________________ 
 
12. Have you had a blood test for coeliac disease related antibodies?  Yes  No 
 
If yes, could you provide the research team with a copy of the results?  Yes  No 
 
13. Have you had a small bowel biopsy to test for coeliac disease?  Yes  No 
 




14. Are you currently on a gluten free diet?  Yes  No 
 
If “No”, proceed to question 18 
 
GLUTEN FREE DIET 




16. On whose advice did you commence this diet? 
 Family member  
 General Practitioner  
 Gastroenterologist / specialist  
 Dietician  
 Naturopath/complementary therapist  
 On outside advice  
 Other _______________________ 
 
17. Did you commence a gluten free diet prior to diagnosis?  Yes  No 
 
If yes, did you recommence eating gluten for your diagnosis?  Yes  No 
 
DIET GENERAL 
18. Are you on any of the following diets (tick all that apply)? 
 Vegetarian  Yes  No 
 Vegan  Yes  No 
 Egg Free  Yes  No 
 Dairy Free  Yes  No 
 Soy Free  Yes  No 
 Nut Free  Yes  No 
 Low FODMAP  Yes  No 
 










HISTORY OF ILLNESS 
20. Do you have a family history of coeliac disease? (tick all that apply)  
 Yes, first degree relative (e.g. mother, father, brother, sister, son, daughter) 
 Yes, second degree relative (e.g. grandparent, grandchild, aunt, uncle, cousin)  
 No 
 
21. Have you been diagnosed with any of the following conditions? 




Autoimmune thyroid disease    
Type 1 diabetes    
Addison’s disease (insufficient adrenal hormones)    
Sjogren’s syndrome (dry mouth and eyes)    
Rheumatoid Arthritis    
Lupus (body attacks healthy tissue and organs)    
Multiple Sclerosis    
Dermatitis herpetiformis (chronic, itchy skin rash)    
Alopecia (hair loss)    
Psoriasis    
Anaemia (iron or B12 deficiency)    
Depression    
Gastrointestinal cancers    
Lactose intolerance    
Mouth ulcers    
Osteoporosis/low bone mineral density/low trauma fracture    
Rickets or osteomalacia (caused by low vitamin D)    
 
 
22. Do you have any other permanent (chronic) or re-occurring conditions?  Yes  No 





23. Have you ever taken prescription reflux or ulcer medications? 
Proton pump inhibitor e.g. Nexium, Somac, Losec, Zoton  Yes  No 
H2-receptor antagonist e.g. Zantac, Rani-2, Tazac  Yes  No 
 
24. Have you ever taken cholesterol lowering medications?  Yes  No 




25. Do you drink alcohol?  Never  Quit  Current 
 
If “Quit” or “Current” how many drinks per week?    
 
26. Do you smoke?   Never  Quit  Current 
 
If “Quit” or “Current” when (approximate date) did you have your last cigarette? ______________ 
 
If “Quit” or “Current” how many years did/have you smoked for?     
 
If “Quit” or “Current” how many cigarettes did/do you smoke per day?     
 
 
Thank you for your time. You have now completed the survey. 
 
